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ABSTRACT 
MECHANISM OF GABAB RECEPTOR-ACTIVATED INCREASES  
IN L-TYPE CALCIUM CURRENT IN THE NEONATAL  
MAMMALIAN HIPPOCAMPUS 
 
 
Andrew Karls, B.S. 
 
Marquette University, 2014 
 
 
 Activation of the metabotropic GABAB receptor has most commonly been 
demonstrated to produce inhibitory effects on neurons, including the attenuation of 
voltage-dependent calcium current.  However, during the early neonatal period in 
mammalian development, activation of GABAB receptors leads to an enhancement of 
calcium current through a specific class of calcium channels, termed L-type channels, 
(because they conduct Long-lasting current) .  This response peaks at 7 days postnatal, and 
is only demonstrated in a subset of cells.  In the work presented here, the signal transduction 
pathway of GABAB receptor-mediated increase of L-type current is described. 
 
 GABAB receptors couple to G proteins, traditionally believed to be Gαi/o.  However, 
previous data from the laboratory suggested that the enhancing effect observed was not due 
to Gαi/o, but a different G protein not previously described in GABAB receptor signaling.  
Indeed, when the Gαq G protein was knocked down in cell culture, the enhancement of L-
type channels was no longer observed.  These data suggest that GABAB receptors couple 
to Gαq G proteins to mediate calcium current enhancement. 
 
 Protein kinase C (PKC) had previously been demonstrated as a requisite member 
of this pathway.  Furthermore, there was precedence for PKC to work through 
calcium/calmodulin-dependent kinase II (CaMKII) to enhance L-type current.  However, 
the isozyme of PKC was not known, nor was the involvement of CaMKII on L-type current 
enhancement.  Confocal imaging analysis suggests PKCα is the isozyme that is activated 
by GABAB receptor activation, and pharmacological studies indicate CaMKII is not a 
participant in this pathway.   
 
 In seeking to inhibit CaMKII signaling, highly specific pharmacological inhibitors 
are often required.  However, several inhibitors that were thought to be specific initially 
demonstrate nonspecific effects.  A newly synthesized molecule, CK59, has been described 
to potently inhibit CaMKII activity (IC50 < 10 µm).   However, data presented here describe 
off-target effects of CK59, specifically its ability to inhibit voltage-gated calcium channels.  
Treatment of cells with CK59 significantly reduced calcium influx in depolarized neurons, 
whereas other CaMKII inhibitors did not change calcium influx.  Thus, CK59 is not a 
useful tool when studying the interplay between voltage-caged calcium channels and 
CaMKII signaling. 
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CHAPTER 1 
INTRODUCTION 
A cell’s ability to receive and integrate external stimuli is critical to maintain 
processes required for its function.  For example, stimulation of cells lining the gut cause 
secretion of enzymes required to break down food and obtain nutrients.  In a similar way, 
the response to extracellular signals in neurons is critical to sensory perception, synaptic 
plasticity, gene expression, and cellular communication via neurotransmission.  One of 
the most common ways neurons respond to extracellular stimuli is modulation of 
intracellular calcium.  Calcium serves as an effective signal, because it is kept very low 
(low nM) within the neuron, but is much higher outside the cell (mM range).  When 
calcium is allowed to enter the cell through various channels or transporters, it stimulates 
an intracellular change crucial to neuronal function or survival.  Thus, the ability to 
modulate calcium entry helps to influence myriad intracellular signals. 
 One of the most common ways to affect calcium entry is to change the behavior 
of ion channels.  This can be done directly, where a change in voltage or binding of a 
ligand directly opens a channel.  Also common are intracellular signaling pathways, 
which cause calcium channels to be modified by various signaling molecules, such as 
protein kinases.  These pathways involve a signaling cascade, where binding of a 
neurotransmitter to its receptor sets in motion a cascade of events.  One example of this 
cascade affecting calcium entry is the binding of the neurotransmitter γ-aminobutyric 
acid (GABA) to the metabotropic GABAB receptor.   
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A central focus of the Mynlieff laboratory is to understand how binding of GABA 
to its receptor leads to an increase in the amount of calcium entering the cell.  Several 
studies have detailed the opposite effect: that GABAB receptor activation attenuates 
calcium entry (Takahashi et al., 1998; Carter and Mynlieff 2004; Perez-Garci et al., 
2013).  However, the Mynlieff lab showed that in hippocampal cell cultures derived from 
rats early in development, GABAB receptor activation increases long lasting (L-type) 
calcium current in a subset of cells (Carter and Mynlieff 2004; Bray and Mynlieff 2009; 
Bray and Mynlieff, 2011).  Furthermore, this response peaks between postnatal day 6 
(P6) and P8 (Bray and Mynlieff, 2009).  The phenomenon of GABAB receptor activation 
leading to enhanced calcium entry had been identified only once before, in non-
mammalian cells of the salamander retina (Shen and Slaughter 1999).  Currently, there 
are still very few reports of GABAB receptor-mediated enhancement of L-type current 
(Park et al., 2010; Im and Rhim 2012), and no complete pathway or mechanism has yet 
been described.  Therefore, the enhancing effect of GABAB receptor activation on 
enhanced L-type current continues to be an area of intense interest in the laboratory. 
Tight regulation of intracellular concentrations is required for proper neuronal 
growth and development (for review, see Michaelsen and Lohmann 2010).  L-type 
channels are the first calcium channels to be expressed in neurons; calcium flowing 
through these channels is responsible for the initiation of regulatory events that may play 
a role in neuronal differentiation (Pravettoni et al., 2000).  Furthermore, the rats used in 
experiments to be detailed here range in age from P6 to P8, roughly equivalent to a 6 
month old human infant (Sengupta 2013).  This time span is commonly associated with 
seizure activity generated in the hippocampus (Korff and Nordli, Jr. 2006).  How 
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regulation of calcium flowing through L-type channels may be involved is unclear, but 
there is emerging corollary evidence that L-type channels may play a role.  First, 
inhibiting L-type channels changes the distribution in chloride transporters necessary for 
establishing a proper chloride ion gradient (Bray and Mynlieff 2009).  Changes in 
expression patterns of the same specific chloride transporters examined by Bray and 
Mynlieff led to epilepsy-associated malformations of cortical development (Aronica et 
al., 2007).  Thus, one hypothesis is that during the rodent neonatal period (roughly 
correlating to the first six months of human life), L-type channel activity is responsible 
for changes that establish a neuron’s identity, including electrical properties.  When L-
type current signaling is disrupted during development, the intrinsic electrical gradients 
cannot be established. Thus, the circuit becomes vulnerable to epileptiform activity, 
where neurons fire excessively in a synchronous manner.  It can be hypothesized that any 
pathway which functions to regulate intracellular calcium levels, such as GABAB 
receptor activation in these cells, is imperative to proper function. 
The principal focus of my research has been to further describe the components of 
the signal transduction pathway, beginning with GABAB receptor activation, and 
resulting in L-type current enhancement.  Using work done by previous members of the 
laboratory as a basis for my studies, I explored what signaling molecules might be 
participating in this pathway; my results presented here suggest a novel mechanism that 
corresponds with the Mynlieff laboratory’s discovery of a novel signaling pathway.  A 
recent report suggests the interplay between GABAB receptors and their regulation of 
intracellular calcium may play a role in Parkinson’s disease, underscoring the importance 
of understanding these data (Hillman et al., 2012). Furthermore, a better understanding of 
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how cells communicate in general provides a better framework for potentially modifying 
the system in certain diseases.   
 
The Hippocampus 
Studies in the Mynlieff laboratory examine dissociated neurons from the murine 
hippocampus.  The hippocampus is part of the medial temporal lobe of the brain, where it 
plays a central role in formation and retrieval of memories.  It is also a well-known site 
for seizure formation.   Morphologically, the hippocampus is composed of a “c”-shaped 
sheet of neurons (the dentate gyrus) folded around another “c”-shaped sheet, known as 
Ammon’s horn (Figure 1.2).  This area can be subdivided into 3 distinct regions, CA1 – 
CA3 (CA is rooted in the Latin term for Ammon’s horn).  The neurons of the pyramidal 
cell layer are densely packed through the CA1- CA3 region; however once it folds under 
the dentate gyrus, neurons are much less dense.  Thus, neurons with their cell bodies 
outside the two cell layers tend to be much more diffuse; in general these cells are 
identified as inhibitory GABAergic interneurons.  The hippocampus is also described 
depthwise with different strata (Figure 1.2).  The stratum oriens is the most superficial 
layer of the hippocampus, and sits above the primarily excitatory glutamatergic cell 
bodies of the stratum pyramidale.  Below the stratum pyramidale sits the stratum 
radiatum, which is enriched in dendrites.  Many of the Schaffer collateral fibers are found 
here, as well as a diverse group of interneurons, rich in dendrites.  Below the radiatum is 
the stratum lacunosum and stratum moleculare, which are often grouped together, as well 
as a host of interneurons.  Finally, the dentate gyrus sits most ventral.  Studies described 
here focus primarily on neurons dorsal to the dentate gyrus, primarily in CA1 and CA3 
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Figure 1.1: Pathways through the 
rodent hippocampus.  Input enters 
via the entorhinal cortex and 
synapses on the granule cells of the 
dentate gyrus (DG).  DG axons 
project to the CA3 region via mossy 
fibers.  CA3 pyramidal neurons 
project to the CA1 region.  Output is 
primarily through the CA1 
pyramidal neurons back to the 
entorhinal cortex.  (Figure courtesy 
of neurosciencenews.com)  
regions; for a more complete description of dentate gyrus structure and function, see 
Scharfman, 2007.   
 
 
 
 
 
The hippocampus is perhaps the most intensely studied brain region; as such, 
network connections and various cell types have been characterized in some detail.  Input 
entering the hippocampus flows unidirectionally via three well-defined pathways 
(Andersen et al., 1973).  First, the entorhinal cortex contains axons that project onto the 
granule cells of the dentate gyrus; this is known as the perforant path.  Second, neurons of 
the dentate gyrus project their axons (known as mossy fibers and thus the mossy fiber 
pathway) onto the pyramidal neurons of the CA3 region.  Third, the CA3 region 
pyramidal neurons contain branching axons that travel out of the hippocampus through 
the fornix, as well as axons that synapse on CA1 pyramidal neurons within the CA1 
region.  Hippocampal output consists primarily of CA1 axons projecting back into the 
entorhinal cortex.  The CA1 region receives mostly excitatory glutamatergic input from 
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the CA3 region; this input is extensively regulated by a network of GABAergic 
interneurons.  These interneurons serve to govern firing rate and ensure it occurs in 
synchrony.  There are at least 16 types of distinct interneurons in the hippocampus; 
twelve synapse onto dendrites of pyramidal cells and four synapse onto other parts of 
pyramidal neurons or onto other interneurons (Somogyi and Klausberger 2005; 
Klausberger and Somogyi 2008; Klausberger 2009). Nearly all (92%) GABAergic 
interneurons in the CA1 region synapse on pyramidal neuron dendrites (Megias et al., 
2001); however, little research has been conducted on the synapses on the cell bodies and 
axons of these pyramidal neurons.  The hippocampus, particularly the superior region 
(mostly CA1 some CA3), contains a relatively high population of GABAergic 
interneurons.  While my hippocampal cell cultures contain a heterogeneous mixture of 
pyramidal neurons and several type of interneurons, these cultures exclude the dentate 
gyrus.  They contain neurons only from the CA1 and CA3 regions, to decrease the 
heterogeneity of the population (see methods).  Furthermore, while hippocampal  
 
 
Figure 1.2: Cross sectional slice of a P7 
rat hippocampus.  Hippocamus was 
frozen, sliced into 20 μM sections, and 
stained with DAPI to visualize nuclei.  
The stratum oriens (SO) is most 
superficial, with the densely packed 
stratum pyramidale (SP) sitting below.  
The stratum radiatum (SR) contains 
interneurons that project to CA. The 
stratum moleculare/lacunosum (SLM) 
sits on top of the dentate gyrus (DG), 
which is densely packed with excitatory 
dentate granule cells.  Scale bar = 100 
µM.   
7 
 
interneurons are divided based primarily on antibody staining and morphology, the 
physiological role for many of these interneurons remains elusive.  Data presented here 
present an opportunity to begin to define the physiological relevance of some of these 
interneuron types, especially during development when maturation of circuitry is 
occurring.    
  
GABAB receptors 
The GABAB receptors that we have demonstrated to enhance calcium current are 
are G protein coupled receptors that are members of the class C7 transmembrane-
spanning G protein coupled receptor family.  The class C family also includes 
metabotropic glutamate receptors, and its members share amino acid sequence identity of 
approximately 30% (Katritch et al., 2013).  Importantly, several important sites such as 
the ligand binding domain, have much higher sequence identities, which allows for the 
development of several structural homology models.  (Katritch et al., 2013).  Thus, much 
of what is known about the various activation states and molecular interactions of the 
GABAB receptor is based on models of the metabotropic glutamate receptor.  However, 
investigators have recently solved the extracellular domain of the receptor, both unbound 
(Geng et al., 2012), and when it is bound to a ligand (Geng et al., 2013).  Cystallography 
data, homology modeling, and cloning work done in the early 1990’s have provided a 
foundation of knowledge about GABAB receptor structure.  It is composed of two distinct 
gene products which encode the GABAB1 and GABAB2 subunits, respectively.  
Physiological characterization showed that a functional receptor requires dimerization of 
GABAB1 and GABAB2 subunits (Kaupmann et al., 1998; Jones et al., 1998; Kuner et al., 
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1999); the GABAB1 subunit contains a motif that causes retention at the endoplasmic 
reticulum (Margeta-Mitrovic et al., 2000).  When GABAB1 and GABAB2 dimerize via a 
coiled coil interaction on their C termini, the retention signal is hidden, and the receptor 
will be trafficked to the membrane (Calver et al., 2001; Margeta-Mitrovic et al., 2001).  
 
 
 
 
 
 
The simplest view of GABAB receptor signaling is that the B1 subunit binds the 
ligand, whereas B2 couples to the G protein (Figure 1.3a).  Homology models have 
suggested the presence of a “venus flytrap” model, where the binding site is between two 
lobes on the B1 N-terminus (Galvez et al., 1999).  The first step in signal transduction is 
the closure of the lobes around the ligand (Galvez et al., 2000).  Interestingly, chimeric 
models where the B2 N-terminus is replaced with the B1 N-terminus decreases ligand 
affinity (Galvez et al., 2001; Geng et al., 2012).  Therefore, while B1 is the site of 
binding, there appears to be intramolecular communication and possible interaction of B2 
Figure 1.3: Schematic structure of GABAB receptors. (a) The ligand binds to the 
GABAB1 subunit, and the G protein couples to the GABAB2 subunit. GABAB1a is shown 
with sushi repeats. (b) Effects of GABAB receptor activation on inwardly rectifying 
potassium currents shown in the presence and absence of auxiliary subunits. KCTD, 
potassium channel tetramerization domain.  Adapted by permission from Macmillan 
Publishers Ltd: [Nature Reviews Neuroscience] (13, 380-394), copyright (2012). 
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to promote the most efficient ligand binding.  Just as chimeric studies were used to show 
the importance of the B2 N-terminus in ligand binding, they were also used to describe in 
detail the components for G protein coupling.  When B2 was swapped with any of the B1 
intracellular loops, the result was formation of a nonfunctional receptor (Margeta-
Mitrovic et al., 2001).  Furthermore, specific point mutations within either intracellular 
loop 2 or 3 can also render the receptor nonfunctional (Havlickova et al., 2002; Duthey et 
al., 2002).  The generation of GABAB subunit knockout mice has generally supported 
chimeric studies.  GABAB1 knockouts do not display electrophysiological or biochemical 
activity when a ligand is present (Prosser et al., 2001; Schuler et al., 2001; Queva et al., 
2003).  However, responses of GABAB2 knockouts can be measured 
electrophysiologically in the hippocampus (Gassmann et al., 2004).  This is suggestive 
that GABAB1 subunits can function autonomously or, more likely, promiscuously with 
other receptors.  Recent evidence has shown GABAB2 functional interaction with M2 
muscarinic receptors, expanding the possibilities beyond simple GABAB1/GABAB2 
heteromers (Boyer et al., 2009).When GABA receptors were cloned, it was expected that 
there would be a host of splice variants and isoforms to correlate with the diverse 
signaling attributed to the receptor (Padgett and Slesinger 2010).  Instead, only two splice 
variants of GABAB1 were discovered, GABAB1a and GABAB1b (Kaupmann et al., 1997).  
GABAB1a and GABAB1b show no physiological or pharmacological distinction when 
expressed in heterologous expression systems (Brauner-Osborne and Krogsgaard-Larsen 
1999; Ulrich et al., 2007).   However, only GABAB1a contains 2 “sushi” domains, 
believed necessary for axonal targeting.  This suggests B1a is primarily axonal, whereas 
B1b is dendritic.  Knockout studies have verified these localizations (Vigot et al., 2006).    
10 
 
GABAB receptor signaling has traditionally been described by its coupling to a 
pertussis toxin-sensitive Gαi/o G protein (Pinard et al., 2010).  Ligand binding causes the 
G protein (both Gα and Gβγ) to release from the receptor in a GTP-dependent fashion.  
Downstream targets of the G protein itself often initiate a second messenger cascade 
which can have a wide range of effects on physiological functions (Figure 1.3).  G  
 
 
 
Figure 1.4: Downstream effectors of GABAB receptors. (a) Presynaptically, GABAB receptors 
decrease both evoked and spontaneous neurotransmitter release. (b) Postsynaptically, GABAB 
receptor activation results in increased outward potassium current, decreased activity of PKA, 
and reduced calcium currents.  Reprinted by permission from Macmillan Publishers Ltd: 
[Nature Reviews Neuroscience] (13, 380-394), copyright (2012). 
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proteins also commonly target ion channels as a way of regulating excitability.  The three  
 most well understood targets of Gαi/o G proteins linked to GABAB receptors are voltage-
gated calcium channels, inwardly rectifying potassium channels, and the enzyme 
adenylate cyclase (Gassmann and Bettler 2012).   
Adenylyl cyclase is the enzyme that converts ATP into cyclic AMP (cAMP), one 
of the most ubiquitous second messengers in neurons.  In this case it is the Gαi/o activated 
by GABAB receptors that inhibits activity of this enzyme (Nishikawa et al., 1997).  By 
doing so, cAMP levels are reduced, thus resulting in reduction of downstream kinase 
activation, specifically protein kinase A (Figure 1.4b).  Of particular interest is that under 
certain conditions, GABAB receptors can actually increase cAMP levels.  While the Gαi/o 
is inactivated by regulator of G protein signaling (RGS) proteins, the βγ subunits inhibit 
the GTPase activity of Gαs during β-adrenergic receptor stimulation.  This leads to 
increased affinity of Gαs for adenylate cyclase.  Thus, GABAB receptor activation can 
indirectly assist in the increase of adenylyl cyclase activity, resulting in increased protein 
kinase A activity (PKA, Robichon et al., 2004).  This is important to work presented here, 
which also examines the ability of GABAB receptors to produce a bidirectional response 
via a different mechanism affecting voltage-gated calcium channel (VGCC) function.  
G-protein inwardly rectifying potassium channels (GIRK channels) open to 
produce a slow inhibitory postsynaptic potential (Figure 1.4b).  This occurs because 
positive potassium ions flow out of the cell, reducing its excitability.  These GIRK 
channels hyperpolarize the membrane potential, and are the primary effectors of GABAB 
receptors postsynaptically (Misgeld et al., 1995).  In contrast to the inhibitory effects in 
P/Q- and N- channels, the currents across GIRK channels are enhanced by the βγ subunit 
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directly (Reuveny et al., 1994; Wickman et al., 1994).  GIRK channels are homo- or 
heterotetramers; it is thought that the subunit composition of the GIRK channel accounts 
for its differing interactions with the Gβγ, and thus accounts for the large differences in 
GIRK channel kinetics in response to GABAB receptor activation (Cruz et al., 2004; 
Padgett and Slesinger 2010).  This hypothesis appears to be partially correct, although the 
recently discovered GABAB auxiliary subunits also appear to play an important role in 
influencing GIRK channel kinetics (Gassmann and Bettler 2012).   
For many years there have been discrepancies about the differing kinetics seen 
when GABAB receptors regulate GIRK channels in native neurons versus those in 
expression systems.  For example, activation kinetics were always much faster in native 
neurons; this difference was thought to be due to the subunit composition of the GIRK 
channel (Gassmann and Bettler 2012).  However, biochemical evidence has shown that 
GABAB receptors can assemble with auxiliary potassium channel tetramerization domain 
(KCTD) proteins (Schwenk et al., 2010).  These four proteins form a homotetramer that 
can bind to the GABAB2 C-terminus (Figure 1.3b).  Expression of these KTCD tetramers 
with GABAB receptors in heterologous expression systems abolished the differences seen 
in these model systems when KCTD proteins were not included (Schwenk et al., 2010).  
Thus, it appears that the GABAB receptor auxiliary subunits may significantly change the 
function of the receptor.  As pointed out by the authors who made the discovery 
originally, KCTD proteins could influence any part of the signaling complex, including 
what the downstream effector or channel of the GABAB receptor may be (Schwenk et al., 
2010). 
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GABAB receptors have been shown to couple to all types of high voltage 
activated calcium channels (P-, Q-, N-, and L-), with the exception of the R channel 
(Mintz and Bean 1993; Guyon and Leresche 1995; Huston et al., 1995; Harayama et al., 
1998; Li and Stern 2004; Vigot et al., 2006).  Dogmatically, ligand binding to the 
GABAB receptor liberates the βγ subunit to directly bind to the presynaptic VGCCs.   
This slows the activation of the VGCC and decreases its activity 10-50% (Figure 1.4a, 
Huston et al., 1990; Menon-Johansson et al., 1993; Guyon and Leresche 1995).  Less 
presynaptic calcium inhibits vesicular neurotransmitter release.  To a lesser degree than 
presynaptic inhibition, GABAB receptor signaling is also involved postsynaptically.  For 
example, in the supraoptic nucleus, release of βγ caused by GABAB receptor activation 
leads to a decrease in firing because of the reduction in calcium currents (10-25%, 
Harayama et al., 1998).  Finally, activation of GABAB receptors has also been shown to 
increase L-type calcium current (Shen and Slaughter 1999; Carter and Mynlieff 2004; 
Bray and Mynlieff 2011; Park et al., 2010).  While there are fewer descriptions of this 
phenomenon, it is not pertussis toxin sensitive (Bray and Mynlieff 2011), and is likely 
mediated by a Gαq G protein which initiates a signaling cascade.  This document will 
spend much time describing what is known about the pathway, and thus it will not be 
detailed presently.   
   
G Proteins 
GABAB receptors are known as G protein coupled receptors (GPCRs) because they 
associate in signaling complexes with molecules known as a guanine nucleotide-binding 
proteins.  Simply referred to as heteromeric G proteins, these complexes are composed of 
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an α subunit, as well as β and γ subunits, which closely associate with each other.  Upon 
ligand binding to the GPCR on the extracellular side of the membrane, the G protein 
associated with the GPCR on the intracellular side of the membrane will become 
activated (Figure 1.5).   The conformational change that takes place within the GPCR 
allows the G protein to exchange bound GDP for GTP on its Gα subunit.  This exchange 
causes the Gα subunit to dissociate from the GPCR and the Gβγ subunit complex.  Both 
the Gα and Gβγ can serve to initiate signal transduction cascades.  Termination of 
signaling occurs when the intrinsic GTPase activity of the Gα hydrolyses GTP to GDP, 
restoring the affinity of the Gα to Gβγ.  Proteins known as GTPase activating proteins 
(GAPs) increase the rate at which hydrolysis occurs; in certain cases, the molecule 
targeted by the G protein may possess GAP activity and thus increase rate of deactivation 
(G protein signaling reviewed in McCudden et al., 2005; Wettschureck and Offermanns 
2005; Milligan and Kostenis 2006).  Bacterial toxins have aided greatly in determining 
the function and molecular mechanisms of various G protein families.  Cholera toxin 
(CTX) produces a constitutively active α subunit of Gαs (Moss and Vaughan 1979; Van 
Dop et al., 1984); pertussis toxin (PTX) causes Gαi/o to remain permanently bound to 
GDP (inactive) and uncouples the heterotrimeric complex of Gαi/o G proteins from their 
GPCR (Katada and Ui 1982; Kurose et al., 1983).   
G proteins are named based on the identity of their α subunit.  They are grouped 
into families, often exerting similar effects, and sharing significant sequence similarity.  
There are currently four families of Gα proteins with a total of 14 members (Simon et al., 
1991).  A broad description of the divisions and functions of various G proteins can be 
found in table 1.  Of particular interest to this project is the Gαq family. The Gαq family 
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comprises 4 members: Gαq, Gα11, Gα14, and Gα15/16 (Mizuno and Itoh 2009).  Gαq is 
found in all tissue types, and its α subunit amino acid sequence is used for comparison of 
sequence identity with other members (reviewed in Mizuno and Itoh 2009).  Gα11 
demonstrates 90% sequence similarity with Gαq, and is also distributed across all tissue 
types.  Gα14 demonstrates 80% sequence similarity with Gαq, and is most commonly 
found in non-neuronal tissues, such as the kidney, liver, and lung; finally, Gα15/16 is also 
not distributed in nervous system, but rather in hematopoetic cells only.  Its α subunit 
demonstrates 57% sequence similarity to that of Gαq.  Structurally, all four  
 
G protein 
family 
Members Distribution Pharmacological 
Inhibitor 
Common 
physiological 
action 
Gαs αs, 
 αolf 
Ubiquitous 
Olfactory 
Epithelium 
Cholera Toxin Activates adenylyl 
cyclase 
Gαi/o αi1, αi2, αi3,  
αo, 
 αz,  
αt-r,  
αt-c,  
αgust 
 
Ubiquitous 
Neuronal 
Neuronl 
Retinal rods 
Retinal cones 
Taste buds 
Pertussis Toxin Inhibits adenylyl 
cyclase, activates 
GIRK channels  
inhibits N-type 
channels 
increases PDE 6 
activity (for rods, 
cones, and taste 
buds)  
 
Gαq αq, α11 
α14 
α15/16 
Ubiquitous 
Kidney, lung 
Hematopoetic 
cells 
YM-254890 (all 
but α15/16) 
Activate β isoforms 
of phospholipase C  
Gα12/13 α12, α13 Ubiquitous  Activate small G 
proteins including 
RhoA 
Table 1: Families of G proteins.  Members are divided based on their α subunit, and described 
by their pharmacology, most common tissue distribution, and general physiological role.  Adapted 
from Wettschureck and Offermanns 2005.   
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isoforms are similar, composed of a helical domain with 5 α helices, a switch region 
(with both α helices and β sheets), and a GTPase domain.  The physiological role of the 
Gαq family is to activate β isoforms of phospholipase C (PLCβ), which in turn catalyzes a 
reaction in which phosphatidylinositol bisphosphate (PIP2) is cleaved into inositol 
trisphosphate (IP3) and diacylglycerol (DAG).  The result of cleaving PIP2 and generating 
these second messengers is to release calcium from intracellular stores (via the IP3 
receptor) and activate protein kinase C (PKC), both of which participate in a range of 
cellular processes (signaling pathway reviewed in Rhee 2001).  All four isoforms of 
PLCβ (β1-β4) are stimulated by the Gαq family and their associated Gβγ, although 
different Gαq isoforms preferably activate different PLCβ isoforms.  For example, the 
Gαq isoform is a poor activator of PLCβ-2, but not the other three isoforms of PLCβ 
(Hepler et al., 1994; Jiang et al., 1994); Gα15/16 can activate only PLCβ 1-3 (Kozasa et al., 
1993).  The mechanism by which the Gαq family members activate PLCβ is unknown; 
however, truncation experiments have shown that the PLCβ C-terminus is required for 
Gαq interaction (Park et al., 1993).  On the Gαq protein, the third helix and linker to the 
fourth β sheet change conformation when PLCβ is activated (Venkatakrishnan and Exton 
1996).  Truncation mutations verified these as essential regions.  In terms of termination, 
it was shown, somewhat surprisingly, that the intrinsic GTPase activity of Gαq was rather 
low; however, in the presence of PLCβ-1, activity significantly increased.  This result 
indicated PLC β-1 acts as a GAP to stimulate hydrolysis of GTP bound to Gαq (Chidiac 
and Ross 1999).  While the first bacterial toxins such as PTX or CTX had no measurable 
action on the activity of Gαq G proteins, recently two compounds have been isolated that  
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modulate Gαq signaling.  The pathogenic bacterium P. multocida produces a protein 
known as PMT, which acts as a mitogen; pharmacologically, this compound appears to 
facilitate Gαq coupling to PLCβ-1 leading to the same response elicited by receptors 
coupled to Gαq family members (Wilson and Ho 2004).  Importantly, PMT does NOT 
activate Gα11 mediated pathways, because the Gα11 isoform is missing a critical region in 
its helical domain where PMT appears to induce activation.  A second modulator, YM-
254890, has been isolated from Chromobacterium culture broth; it reduces the enhanced 
calcium signals induced by Gαq, Gα11, and Gα14, but not Gα15 (Takasaki et al., 2004).  
While the molecular mechanism is not yet known, YM-254890 is the most specific 
inhibitor of Gαq signaling currently available.  
 
Voltage-gated Calcium Channels  
Calcium entry into neurons is a tightly regulated process.  Various intracellular storage 
sites, membrane transporters, and ion channels collectively determine the concentration 
of calcium within the cell.  One well studied mechanism for calcium entry is the opening 
of voltage-gated calcium channels (VGCC) in response to depolarization.  These 
channels are heteromers, composed of an α1 pore-forming subunit, as well as auxiliary 
Figure 1.5: Schematic structure 
of G protein activation.  Agonist 
binding to the receptor causes 
GDP to be exchanged for GTP, 
the complex to dissociate from 
the receptor, and the α and βγ 
subunits to initiate a signaling 
cascade.  Reprinted by 
permission from Macmillan 
Publishers Ltd: [Nature] (420, 
716-717), copyright (2002). 
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subunits which modify expression and kinetics of the channel.  Two classes of VGCC 
have been identified, based on whether they activate at low voltages (LVA, Va ~ -46 mV, 
(Klockner et al., 1999) or high voltages (HVA, Va ~ +10 to -20 mV, Catterall et al., 
2005).  VGCCs are subdivided based on sequence identity, pharmacology, and kinetics.  
Collectively, there are a total of 10 α1 subunits classified into three families (reviewed in 
Ertel et al., 2000, table 2).  Within these families, there is greater than 70% sequence 
identity, and less than 40% identity between families (Catterall 2011).  LVA channels 
(Cav 3.x) are known as T-type channels; they produce a transient current which helps 
regulate excitability in neurons, aid in secretion in the kidney and liver, and regulate 
smooth muscle contraction and proliferation (Cueni et al., 2009; Iftinca and Zamponi 
2009).  Cav 2.x channels are associated with neurotransmitter release in the central 
nervous system and at the neuromuscular junction (Weiergraber et al., 2006; Snutch 
2005; Nimmrich and Gross 2012). The Cav 1.x family contains isoforms 1.1 – 1.4.  Cav 
1.1 channels are found in the transverse tubules of skeletal muscle (Flucher and Franzini-
Armstrong 1996) where they are required for excitation contraction coupling (Rios et al., 
1992).  Cav 1.4 channels are located in retinal photoreceptors and bipolar cells of the eye, 
and are necessary for phototransduction (Baumann et al., 2004).  Cav 1.2 channels are 
found in cardiac and smooth muscle, and function in excitation-contraction coupling 
(Striessnig 1999).  Cav 1.3 channels are located on sensory cells, such as cochlear hair 
cells, functioning to promote neurotransmitter release (Michna et al., 2003).  Importantly, 
Cav 1.2 and Cav 1.3 are also both found in neurons.  In neurons, Cav 1.2 channels are 
localized primarily postsynaptically on dendritic shafts and spines (Di Biase et al., 2011); 
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Cav 1.3 channels are located preferentially on proximal dendrites and cell bodies (Hell et 
al., 1993).   
 
 
The α1 subunit of Cav’s is a large protein (190-250 kDa) comprising four domains 
(I-IV, Figure 1.6a).  Each domain contains six membrane-spanning segments (S1-S6).  
Within the transmembrane segments, S4 is the voltage sensor, and the loop between S5 
and S6 serves as the selectivity filter and determines ionic conductance (Catterall 2011).   
The intracellular loops serve as sites where protein-protein interactions occur.  For 
example, G proteins have been shown to regulate N-type channels between domains I and 
II, the same loop where the auxiliary β subunit associates (De Waard et al., 1997; Herlitze 
et al., 1997).  Furthermore, the loop between domains II and III is the site of direct 
interaction with SNARE proteins for Cav 2.x channels (Sheng et al., 1994; Rettig et al., 
1996).  The heavily spliced C-terminal end of neuronal calcium channels contains an IQ-
like motif that can interact with calcium binding proteins such as calmodulin (Lee et al., 
Channel 
Identification 
Voltage 
Activation  
α1 Subunit 
identification 
Pharmacological 
antagonists 
Common tissue 
distribution 
L-type HVA Cav 1.1 – 1.4  Dihydropyridines All muscle types, 
neurons, retinal 
cells  
P/Q-type HVA Cav 2.1 ω-Agatoxin IVA Neurons, heart, 
pancreas 
N-type HVA Cav 2.2 ω-Conotoxin 
GVIA 
Neurons 
R-type HVA Cav 2.3 SNX-483 Neurons, heart, 
testes 
T-type LVA Cav 3.1 – 3.3  Ethosuximide Brain, kidney, 
placenta 
Table 2: Divisions of voltage-gated calcium channels based on pharmacology, kinetics, and 
sequence identity of the pore-forming α1 subunit.  Adapted from Ertel et al., 2000.   
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1999); perhaps most interestingly, L-type calcium channels ( can regulate transcription 
when a spliced fragment binds to a nuclear protein (Gomez-Ospina et al., 2006).  In 
addition to the central pore-forming α1 subunit, VGCC complexes associate with several 
auxiliary subunits (Figure 1.6b).  The α2 and δ subunits are linked by disulfide bonds 
(Gurnett et al., 1996) and, along with the intracellular β subunit, help regulate trafficking, 
surface expression, α1 stability, and kinetics (Buraei and Yang 2013; Dolphin 2013).  
Some types of calcium channels also associate with transmembrane γ auxiliary proteins 
as well, and its effects are determined based on the isoform of beta subunit expressed  
 (Yang et al., 2011).   
 
 
 
Figure 1.6: 2D and 3D 
structure of voltage-gated 
calcium channels.  (A) 
Structure of the α1 subunit is 
comprised of four domains, 
each with 6 membrane-
spanning helices.  Interacting 
molecules, such as PKC, 
CaMKII, and the G protein βγ 
subunit modulate channel 
activity via association with 
the intracellular N- and C- 
termini, or intracellular loops. 
Figure adapted with 
permission from Cold Spring 
Harbor Laboratory Press. 
Catterall W.A., Cold Spring 
Harb Perspect Biol 
2011;3:a003947.  (B) Calcium 
channel complex with 
auxiliary subunits embedded 
in the membrane.  These 
subunits influence trafficking, 
surface expression, and 
behavior of the channel itself.  
Figure courtesy of Dr. Tuck 
Wah Soong, Yong Loo Lin 
School of Medicine, National 
Singapore University.  
 
A. 
B. 
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The focus of much of this work involves the increased calcium flowing through 
neuronal L-type (Cav 1.2 and 1.3) LTCCs.  These LTCCs can be distinguished from other 
VGCCs by their sensitivity to dihydropyridines (Kanngiesser et al., 1988).  However 
there is not a pharmacological means to separate the 4 isoforms of LTCCs; a series of 
knockout studies and experiments done in heterologous expression systems have 
attempted to describe the differences in function.  Global knockout of Cav 1.2 led to 
embryonic lethality because of its importance in the heart (Seisenberger et al., 2000).  
However, conditional knockouts of Cav 1.2 in the cerebral cortex and hippocampus 
showed a loss of late phase long term potentiation and impairment of spatial memory 
formation (Moosmang et al., 2005; White et al., 2008).  These data were associated with 
decreased cyclic AMP response element (CRE) dependent transcription in the CA1 
region of the hippocampus, linking Cav 1.2 with impairment in memory formation.  The 
generation of Cav 1.3 knockout animals has suggested a specific function for this LTCC 
subtype as well.  Studies examining these animals revealed no obvious phenotypic defect 
or problems with motor function (Platzer et al., 2000).  Instead, Cav 1.3 mice are deaf, 
corresponding to a role for L-type current in cochlear hair cells (Platzer et al., 2000).   In 
addition, conditional knockout of Cav 1.3 also showed diminished slow 
afterhyperpolarization, an attribute often associated with increased learning and memory 
(Gamelli et al., 2011).  
 Several biophysical differences described between Cav 1.2 and Cav 1.3 are based 
primarily on work done in Xenopus oocytes.   First, the activation threshold for Cav 1.3 is 
substantially more negative (around -55 mV) than for Cav 1.2 (around -30 mV, 
Lipscombe et al., 2004).  This means that Cav 1.3 channels may activate at 
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depolarizations that are below threshold for action potential generation, which could 
indicate involvement in different signaling pathways.  Second, dihydropyridines do not 
antagonize channels equally (Xu and Lipscombe 2001). For example, the sensitivity to 
LTCC antagonist nimodipine varies widely: IC50 for Cav 1.2 is 139 nM, whereas for Cav 
1.3 it is 3 µM (Xu and Lipscombe 2001).  Thus, early studies using a low micromolar 
concentration may still have some LTCC contribution to overall current.  Finally, Cav 1.2 
channels open significantly faster than do Cav 1.3 channels (Xu and Lipscombe 2001).  
Notably, these studies were done in heterologous expression systems, where auxiliary 
subunits and potentially other interacting proteins were missing.  Whether these 
differences exist in native neurons is unknown.   
Not only are there functional differences in the properties of Cav 1.2 and Cav 1.3, 
but there are differences in expression patterns as well.  80% of LTCCs in the brain are 
composed of the Cav 1.2 isoform compared to 20% Cav 1.3 (Hell et al., 1993).  However, 
during hippocampal development, the composition is changing.  During the early 
neonatal period, expression of Cav 1.2 was relatively high, but began to decrease by P12 
(Kramer et al., 2012). This is in contrast to Cav 1.3, whose expression levels were low at 
P0 but increased steadily into adulthood (Kramer et al., 2012).  Thus, any developmental 
phenomenon that correlates with a change in LTCC may involve the Cav 1.2 isoform, 
because of its relatively higher abundance during development.   
 
Protein kinase C 
Protein kinase Cs (PKCs) are a family of serine/threonine protein kinases that serve as 
secondary effectors in diverse pathways, from immune responses to regulation of 
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transcription.  Currently, there are 15 known isozymes of PKC, with divisions based on 
requirements for activation (table 3, reviewed in Zeng et al., 2012; Wu-Zhang and 
Newton 2013).  Conventional isozymes require both DAG and calcium to be activated, 
whereas novel isozymes require DAG but not calcium.  Atypical PKCs require neither 
calcium nor DAG for activation.  Many PKC isozymes may exist within a single cell, 
though their method of activation and localization may be different (Roisin and Barbin 
1997).  Therefore, it is possible for many PKCs to regulate the activity of a single cell, 
depending on the subcellular localization of PKC.  Structurally, PKCs are generally  
comprised of regulatory domains (C1 and C2) and a catalytic domain (C3 and C4), 
connected by a linking domain (Figure 1.7, PKC structure reviewed in Steinberg 2008).  
There is also a pseudosubstrate that binds the catalytic domain.  The C1 domain contains 
the binding site for DAG as well as phorbol esters, which are structural analogs of DAG 
that  mimic its activity.  Work presented here focuses on the actions of specific 
conventional and novel isozymes of PKC because the effect of GABAB receptor  
activation on calcium current is mimicked by phorbol ester activation (Bray and Mynlieff 
2011). The C2 domain binds phosphatidylserine (PS) and calcium in conventional 
isozymes, but sequence alignment shows the calcium binding segment of the protein is 
absent in novel and atypical PKCs; thus there is no calcium required for activation of 
PKC Family Isoforms Requirements for 
activation 
Phorbol ester 
sensitivity 
Conventional α,βI, βII, γ Calcium, DAG, 
phospholipids 
Sensitive 
Novel δI, δII, δIII, ε, η, θ DAG, phospholipids Sensitive 
Atypical ι, ζ, λ,  Phospholipids Insensitive 
 Table 3: 3 Families of PKC isozymes are divided based on their requirements for activation.  
Only the conventional and novel isoforms are sensitive to phorbol esters.   
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these isozymes.  To become catalytically active, the C1 domain must bind DAG; 
anchoring proteins help position PKCs near the membrane. A phospholipid, most 
commonly PS, also embedded in the membrane, binds to the C2 domain, which causes a 
conformational change in the PKC such that the pseudosubstrate is removed.  For 
conventional isozymes, binding of calcium to the C2 domain increases its affinity for PS.  
With the pseudosubstrate removed, other proteins such as receptor for activated C kinase  
(RACK) help position PKCs close to their substrates (Schechtman and Mochly-Rosen 
2001).  The active site of the catalytic domain is a bilobal structure, which forms a cleft.  
It is within this cleft that both ATP and the substrate bind.  Importantly, a hallmark of 
PKC activation is the necessity for translocation to the plasma membrane.   
All PKC isozymes are expressed in the mammalian central nervous system.  
However, their expression levels vary widely during development (Roisin and Barbin  
1997).   For example PKC γ is not expressed embryonically; only after P14 is any 
expression detectable when it begins to rise rapidly.  This is in contrast to an isoform 
such as PKC ε, where expression is already high at the earliest time point examined, E17.  
It continues to increase, though much more gradually than PKC γ.  Expression also varies 
depending on the tissue examined.  In cardiac tissue, PKCα is expressed at a relatively  
 
Figure 1.7: Domain 
classifications of the 3 PKC 
families. PS, 
phosphotidylserine binding 
domain; C1a, C1b, C2, 
calcium binding domains; 
C2L, calcium-like domain; 
C3 and C4, catalytic domain.  
Adapted by permission from 
Macmillan Publishers Ltd: 
[Journal of Investigative 
Dematology] (129, 2330-
2332), copyright (2012). 
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high level in embryonic day 14 (E14) rats, with expression peaking in the neonate. As the 
animal ages, PKCα expression decreases threefold by adulthood (Rybin and Steinberg 
1994).  In hippocampal tissue, PKCα is low at E17 and steadily increases into adulthood.  
At P7, expression has reached approximately half its maximal expression and has 
increased almost fivefold from embryonic levels (Roisin and Barbin 1997).  These 
expression data are pertinent for experiments attempting to determine the identity of a 
particular isozyme at a given age.   
PKCs have been shown to phosphorylate L-type channels on both the I-II and II-
III intracellular loops (Zamponi et al., 1997).  How this phosphorylation modifies channel 
behavior and L-type current is still not clear, as both an increase and a decrease in L-type 
current have been reported.  Differences in response vary with cell type as well as with 
the isozyme of PKC that is activated.  For example, when α-adrenergic receptors were 
stimulated in cardiac myocytes, L-type current was enhanced in a PKC dependent 
manner.  Notably, this pathway also required the activity of calcium/calmodulin 
dependent kinase II (CaMKII, O-Uchi et al., 2008).  In heterologous systems, PKC 
activation with phorbol esters reduced whole cell current of Cav 1.3 channels (Baroudi et 
al., 2006).  Furthermore, single channel recording of Cav 1.3 channels showed PKC 
activation decreased mean open time, increased mean closed time, and thus led to a 
reduction in open probability (Chahine et al., 2008).  In some cases, L-type current is not 
affected at all.  In dorsal root ganglion neurons obtained from embryonic mice, PKC 
activation did not change L-type current while decreasing N-type current (Gross and 
MacDonald 1989).  Most important to the work presented here, GABAB receptor 
mediated calcium enhancement through L-type channels in neonatal hippocampal 
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cultures requires PKC activity (Bray and Mynlieff 2011).  When a host of inhibitors are 
used, enhancement is abolished.  Conversely, when phorbol esters are used to mimic 
activation, the enhancing response is observed.  Thus, it is difficult to make broad 
statements about the functions of PKCs and L-type calcium channels because any change 
in condition (source of cells, age of the animal, isozyme of PKC) seems to produce a 
unique response.   
 
Calcium/Calmodulin-dependent Protein Kinase II 
CaMKII is found throughout the brain, where it makes up 1-2% of total protein.  
Structurally, it has a unique arrangement; there are twelve functional domains attached to 
a gear-shaped core (Fink and Meyer 2002).  The twelve subunits are grouped into what 
appears to be two stacked hexamers; each subunit contains a catalytic, autoregulatory, 
and association domain (Figure 1.8).  There are two primary subunits in neurons, α- and 
βCaMKII.  Isoforms have a high sequence identity, with the exception of a 30 amino acid 
insertion in the β isoform.  As a serine/threonine kinase, the catalytic domain binds both 
ATP and substrate; however the autoregulatory domain contains a pseudosubstrate site 
that binds to the catalytic domain, preventing catalytic activity.  Perhaps the most 
important residue of CaMKII is Thr 286 (or Thr 287 in βCaMKII).  When this residue is 
phosphorylated, the pseudosubstrate can no longer associate with CaMKII and 
autoinhibition is removed, and thus the catalytic domain is active.  In a stepwise process, 
CaMKII will autophosphorylate and become active, even if calcium and calmodulin are 
no longer present (for more detailed review on CaMKII activation, see Hudmon and 
Schulman 2002b; Hudmon and Schulman 2002a).  Studies have shown that L-type 
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channels are substrates for CaMKII.  Both the α1 subunit (Hudmon et al., 2005) and 
specific beta isoforms of Cav 1.2 (Abiria and Colbran 2010) are shown to be 
phosphorylated.  In either case, the calcium currents are enhanced through calcium-
dependent facilitation, with sites of phosphorylation on the Cav 1.2 α1 subunit having 
been identified (Blaich et al., 2010).  Cav 1.3 channels are also phosphorylated by 
CaMKII, but in a more indirect manner.  CaMKII enhancement of Cav 1.3 currents 
occurs only in the presence of the protein densin, which has a binding site on the C-
terminal tail of Cav 1.3 (Jenkins et al., 2010).  Neither CaMKII nor densin alone will 
produce this current enhancement, but together, the two augment L-type current during 
repetitive stimuli.  Thus, both neuronal forms of L-type channels have CaM binding sites, 
both are substrates for CaMKII, and both demonstrate current enhancement when 
phosphorylated by CaMKII.  Since PKC, a known component of the pathway by which 
GABAB receptors lead to L-type current enhancement, has also been shown to 
phosphorylate CaMKII, and since CaMKII can enhance L-type current, part of the work 
described herein was to examine the potential role CaMKII may play in the enhancement 
of L-type current by GABAB receptors.  
The current research focuses on determining the G protein that mediates calcium 
current enhancement, the isozyme of PKC that is involved in the pathway, and whether or 
not CaMKII participates in L-type calcium current enhancement.   
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Figure 1.8: Domain organization 
and assembly of CaMKII. (a) A 
single subunit of CaMKII includes, 
a regulatory, catalytic, and 
oligomerization domain. (b) Twelve 
subunits assemble into a double 
hexemer.  The highly homologous 
βCamKII subunit includes an F-
actin localization insert for 
trafficking to the post-synaptic 
density.  Adapted from Current 
Opinion in Neurobiology, 12(3). 
Fink, C.C. and Meyer T., Molecular 
mechanisms of CaMKII activation 
in neuronal plasticity, pp. 293-299, 
Copyright (2002), with permission 
from Elsevier. 
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CHAPTER 2 
MATERIALS AND METHODS 
Isolation of hippocampal neurons by cell culture 
 All animal protocols were approved by the Marquette University Institutional 
Animal Care and Use Committee and followed guidelines provided by the United States 
Public Health Service.  Hippocampal neurons were isolated by a method that is specific 
for postnatal rats and has been shown to keep neurons alive for up to three weeks in 
culture (Mynlieff 1997).  Sprague-Dawley rat pups aged 6-8 days postnatal were 
anesthetized with CO2 and immediately sacrificed by decapitation.  The head was placed 
in 70% ethanol for 3 minutes for sterilization, then rinsed in sterile rodent Ringer’s 
solution (146 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 11 mM 
ᴅ-glucose, pH 7.4 with NaOH).  Dissections were performed within a NuAire table top 
horizontal airflow workstation (Plymouth, MN) using sterile technique.  The hippocampi 
were excised from the brain and placed into cold (5˚C) sterile rodent Ringer’s solution 
with glucose bubbled with 100% oxygen.  Hippocampi were sliced into sagittal sections 
and transferred into PIPES-buffered saline (120 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 
mM MgCl2, 25 mM ᴅ-glucose, 20 mM piperazine-N,N’-bis[2-ethanesulfonic acid], pH 
7.0 with NaOH).  The superior region of the hippocampi was isolated to reduce 
heterogeneity of cultured neurons.  The superior region was further cut into 1 mm3 
sections and placed in a sterile 3 mL glass vial.  1 mL of 0.5% trypsin and 0.01% DNase I 
(Sigma-Aldrich, St. Loius, MO) in PIPES-buffered saline was added to the vial.  Tissue 
was incubated at room temperature for 30 minutes with 100% oxygen blown over the top 
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of the solution to allow the trypsin to permeate the tissue.  A second incubation at 37˚C 
for one hour followed, to maximize the proteolytic activity of the enzyme.  The tissue 
was rinsed with 1 mL trypsin inhibitor solution (1 mg/mL trypsin inhibitor, Type II-O: 
chicken egg white (Sigma-Aldrich, St. Louis, MO) and 1 mg/mL bovine serum albumin) 
in rodent Ringer’s solution, then rinsed with Neurobasal-A growth media fortified with 
B27 supplement (Life Sciences, Carlsbad, CA), 0.5 mM glutamine and 0.02 mg/mL 
gentamicin.  The tissue was placed in 1 mL fresh growth media and vigorously triturated 
with a fire-polished Pasteur pipette. For electrophysiological experiments cells were 
plated on 35 mm sterile culture dishes previously coated with poly-ʟ-lysine (MW 38,500 
– 60,000, Sigma –Aldrich, St. Louis, MO) dissolved in 0.15 M boric acid (pH 8.4 with 
NaOH), as described in Mynlieff (1997).  For calcium imaging experiments, cells were 
plated on a glass 22x22 mm coverslip coated with poly-ʟ-lysine.  For confocal imaging 
experiments, 75 μL of cell culture suspension was placed onto the poly-ʟ-lysine-coated 
glass center of a modified plastic cell culture dish (MatTek Corporation, Ashland MA).  
Neurons settled at the bottom of the dish before adding 1 – 2 mL of fresh media per dish.  
Dishes were then placed in a 5% CO2 water-jacketed sterile incubator maintained at 37˚C  
 
Figure 2.1: Appearance of neurons in 
culture after 24 hours.  Cells appear 
spherical and many have begun to 
display characteristic branched 
morphology.  Bright field image taken at 
40x magnification.  Scale bar = 20 µM.   
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for 24 –48 hours (Figure 2.1).    
The use of cultured neurons within 20 – 24 hours for electrophysiological 
recording provides time for reinsertion of channels and receptors that may have been 
sheared off during enzymatic and mechanical digestion.  Furthermore, process outgrowth 
is minimized, allowing for voltage control over the entire cell and preventing space clamp 
problems characteristic of electrophysiological recordings performed on neurons with 
long processes.  Previous data from the laboratory showed that neurons in culture are still 
able to fire and display characteristic electrophysiological properties after enzymatic and 
mechanical digestion (Mynlieff 1997; Mynlieff 1999).  Importantly, the U-tube delivery 
system of pharmacological compounds provides a means to apply compounds to a much 
smaller group of cells minimizing exposing the rest of the population of neurons to these 
compounds in the same culture dish.   
 One advantage to calcium imaging versus electrophysiology its high throughput.  
Electrophysiology samples only one cell at a time, whereas data acquisition via calcium 
imaging allows for measuring calcium influx in up to 50 cells per capture.  A second 
advantage of calcium imaging is that cells with growing processes can easily be included 
in recordings.  This is more difficult in electrophysiological experiments because of space 
clamp problems in cells with long axons or dendrites.  Thus, while electrophysiology 
provides a much more accurate temporal resolution, calcium imaging offers some distinct 
advantages when used to measure calcium influx.  
 Culturing neurons for confocal microscopy allows the experimenter to treat with 
various compounds, then fix the cells in order to understand changes that those 
compounds may have caused.  For example, activation of GABAB receptors is thought to 
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mobilize PKC and cause its translocation from the cytosol to the membrane of the 
neuron.  By adding GABAB agonist baclofen to the culture and fixing it immediately, the 
movement of PKC can be assayed via immunostaining.  This type of direct application 
and image analysis is more difficult in a slice, where pharmacological treatment will 
likely not reach all neurons in the slice.  Furthermore, the detail of changes occurring 
within a single cell in isolation is easier to resolve than examining the changes of a single 
cell within a densely populated hippocampal slice.   
 The use of hippocampal cell cultures isolated from postnatal rats provides a useful 
system to study a GABAB receptor-mediated response.  While embryonic cultures 
contain a large percentage of excitatory pyramidal neurons, postnatal cultures contain a 
greater percentage of GABAergic interneurons.  Indeed, cultures from a 7 day postnatal 
rat showed 41.8 ± 5.0% of the neurons were immunoreactive for anti-GABA antibodies, 
suggesting these cells were inhibitory interneurons (Mynlieff 1997).  A complication of 
working with primary hippocampal cultures is that there is no way to select for cell type 
specificity.  For example, there are at least 16 types of inhibitory interneurons based on 
electrophysiological and immunocytochemichal profiles, as well as a large percentage of 
pyramidal neurons; in either calcium imaging or electrophysiology, it cannot be 
determined what type which type neuron is being examined without post-recording 
immunolabeling or single cell PCR.   
 
Protein preparation and Western blotting 
To prepare protein samples for Western blot analysis, whole hippocampal tissue 
samples were isolated from P6-P8 rats by sacrificing the rat and excision of the 
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hippocampus as described above, followed by homogenization of the tissue in ice-cold 
sucrose buffer (250 mM sucrose, 10 mM Tris, 10 mM HEPES, 1 mM EDTA, pH 7.2) 
with fresh protease inhibitors (1 ug/mL leupeptin, 0.5 mg/mL pepstatin, 0.5 mg/mL 
Pefabloc, Sigma-Aldrich, St. Louis MO).  To isolate membrane-bound proteins, 
homogenized tissue was centrifuged at 3,622 x g for 10 minutes at 4˚C, followed by 
centrifugation of the supernatant at 39,104 x g for 30 minutes.  The pellet from this 
centrifugation step was resuspended in sucrose buffer with protease inhibitors and stored 
at -80˚C until samples were analyzed via Western blot.  In order to prepare cell culture 
samples for Western blot analysis, hippocampal cultures were obtained from 8 rats, 
yielding 24 dishes. Each dish was rinsed twice in ice cold phosphate buffered saline 
(PBS, 134.4 mM NaCl, 4.36 mMKCl, 10.56 mM Na2HPO4, 1.66 mM Na2H2PO4, pH 7.4 
with HCl).  1 mL of sucrose buffer with protease inhibitors was added to each of the 24 
dishes, neurons were scraped from the dishes, and the suspension was centrifuged at 
30,427 x g for 10 minutes.  The pellet was resuspended in sucrose buffer with protease 
inhibitors and spun at 3,622 x g for 10 minutes. The supernatant was spun a final time at 
48,497 x g for 30 minutes.  The resulting pellet was resuspended in 30 µL sucrose buffer 
with protease inhibitors and stored at -80˚C until samples were analyzed by Western blot.  
To increase protein yield in the preparations, in certain experiments the cytosolic and 
membrane fractions were separated using ultracentrifugation based on a protocol from 
Wang et al., (2003). Cells were washed in Wang’s buffer (20 mM Tris, 2.5 mM EGTA, 1 
mM EDTA, 100 mM NaF, pH 7.5 with HCl).  Protease inhibitors listed above were 
added, plus 2 mM dithiolreitol after 2 rinses in Wang’s buffer.  The neurons were scraped 
and spun at 30,427 x g for 8 minutes.  The pellet was resuspended in Wang’s buffer and 
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spun at 4,492 x g for 10 minutes.  The supernatant was collected and spun at 100,000 x g 
for 45 minutes. After this spin, the supernatant was collected and retained as the cytosolic 
fraction.  The pellet was resuspended once more in Wang’s buffer plus 0.1% Triton-X 
100.  The suspension was spun at 30,427 x g for 15 minutes, and the supernatant was 
retained as the membrane fraction.   All spins were done at 4˚C.  Protein concentrations 
were measured with a biophotometer (Eppendorf North America, Hauppauge NY).   
 NuPage lithium dodecyl sulfate sample buffer (Life Sciences, Grand Island, NY) 
and reducing agent (500 mM dithiothreitol in PBS) were added to protein preparations 
and heated to 70˚C for 10 minutes.  Preparations were run on a 12% Bis-Tris Novex 
Minigel® (Life Sciences, Grand Island, NY). Proteins were transferred onto a 
polyvinylidene difluoride membrane with a pore size of 0.45 µM.  Membranes were 
washed for 5 minutes with PBS, then blocked for 1 hour with PBS plus 0.05% Tween, 
5% nonfat dry milk, and 0.1% bovine serum albumin at room temperature.  The 
membranes were decorated with primary antibodies added to the PBS blocking solution 
by rocking them overnight at 4˚C using antibodies listed in Table 4.  Membranes were 
then brought to room temperature, rinsed in PBS with 0.05% Tween, and probed with 
either goat anti-rabbit or goat anti-mouse horseradish peroxidase conjugated secondary 
antibody (table 4) for 90 minutes at room temperature.  The secondary antibodies were 
rinsed from the membrane with PBS and 0.05% Tween, protein bands were visualized on 
classic blue autoradiography film (Molecular Technologies, St. Louis, MO.) after a 5 
minute exposure to SuperSignal West Dura Extended Duration chemiluminescent 
substrate (Pierce, Rockford IL).   
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To quantify protein visualized via Western blotting, the integrated optical density 
(IOD) of each band was measured using Labworks 4.6 software (UVP, Inc., Upland CA).  
To control for gel loading, each lane was loaded with the same amount of protein as 
determined by measurement on a biophotometer.  This was further controlled for by 
dividing the IOD for each protein of interest by the IOD of a control antibody (α/β-
tubulin, Table 4) in the same lane.  At least two separate samples were analyzed for each 
experiment. 
Primary Antibody Source Host Species Dilution  Application 
Gαq alpha subunit Genetex Rabbit 1:500; 1:1000 Western blot; 
immunostaining 
Gα11 alpha subunit Genetex Rabbit 1:1000 Western blot 
α/β tubulin Cell Signaling 
Technologies 
Rabbit 1:2000 Western blot 
GABAB receptor 
B1 subunit 
Neuromab Mouse 1:1000 Immunostaining 
GAD-6 
 
Hybridoma 
Bank 
Mouse 1:2000 Immunostaining 
     
Secondary  
Antibody 
Source Species Dilution Application 
Dylight 488 
 
Thermo-
Pierce 
Goat-Anti 
Rabbit 
1:1000-1:2000 Immunostaining 
Dylight 550 Thermo-
Pierce 
Goat-Anti 
Mouse 
1:1000-1-2000 Immunostaining 
HRP-conjugated Thermo-
Pierce 
Goat-Anti-
Rabbit 
1:2000-1:2500 Western blot 
Table 4: List of primary and secondary antibodies used in experiments. 
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Calcium Imaging 
Cultured neurons on glass coverslips were incubated in 5 μM Fura-2 
acetoxymethyl ester (Fura-2 AM, Life Technologies, Carlsbad CA) in calcium imaging  
Ringer’s solution (CIR, 154 mM NaCl, 5.6 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM 
HEPES, 11 mM glucose, pH 7.4 with NaOH) for 1 hour at room temperature in the dark.  
Cells were rinsed and incubated for 30 min at room temperature in CIR without Fura-2 
AM to allow for de-esterification.  Depolarization was induced by perfusion with  high 
potassium solution (100 mM NaCl, 50 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM 
HEPES, 11 mM glucose, pH to 7.4 with NaOH) for 30 seconds to open voltage-gated 
calcium channels (Figure 2.2). Throughout experiments, CIR was continually perfused at 
a rate of 2 mL/minute.  Application of high KCl and/or pharmacological agents were 
perfused at approximately 3 pSi, producing perfusion at a rate greater than 5 times that of 
CIR perfusion.Each experiment consisted of an initial perfusion of KCl alone, followed 
by coapplication of KCl and pharmacological agents (Table 5).  A final KCl stimulation 
was performed after drug treatment.  The initial and final KCl responses were averaged 
Figure 2.2: Image of cultured cells after 24 hours loaded with ratiometric Fura-2 AM dye.  
(Left) field of cells under nonstimulating conditions. (Right) same field of cells stimulated 
with 50 mM KCl show characteristic change in fluorescence. 
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and compared with the response of KCl plus pharmacological agents.  These agents were 
perfused onto the cells for 15 seconds before addition of high KCl solution.  Cells were 
excited at 340 and 380 nm, and emissions were measured at 510 nm using Slidebook 5.0 
software (Intelligent Imaging Innovations, Denver CO). The ratio of the emissions 
intensity when Fura-2 is excited at 340 and 380 nm is directly correlated to changes in 
intracellular calcium (Grynkiewicz et al., 1985).  Control experiments were performed in 
which the cell was stimulated 3 consecutive times with KCl.  The initial and final 
responses were averaged together, and compared with the middle response.  This allowed 
for determination of inherent variability within the system.  The standard deviation for 
the middle response, compared to the average of the initial and final responses, was 
±11.20%.  In order for a cell to be classified as “increasing” or “decreasing” in response 
to 10 µM baclofen treatments during depolarization, a neuron had to show a response of 
± 21.4% that of KCl controls, which represented two standard deviations from control 
values.  Average data represent the mean ± SEM. 
 
Confocal imaging 
Whole hippocampi from P6-P8 rats were excised and fixed in 4% 
paraformaldehyde for 30 minutes at 4˚C.  Hippocampi were cryoprotected in PBS 
solution containing 30% sucrose for 90 minutes at 4˚C.  The tissue was embedded in 
optimal cutting temperature mounting medium (OCT, Sakura Finetek, Torrance, CA) and 
frozen on dry ice.  20 µM transverse sections were sliced on a cryostat and placed on 
glass slides.  Hippocampal sections were permeabilized in PBS with 0.5% Triton X-100 
for 20 minutes, then blocked for nonspecific binding with 10% goat serum (Life 
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Sciences, Carlsbad, CA) in PBS with 0.05% Triton X-100 for 60 minutes.  Primary 
antibodies were made in PBS with 0.05% Triton X-100 and 0.1% goat serum and were 
incubated with the sections for 2 hours at room temperature.  A list of primary antibodies 
used can be found in table 4.  After incubation, sections were rinsed 3 times in PBS 
before addition of Dylight 488- and 550-conjugated secondary antibodies (Thermo 
Scientific, Rockford IL) for 1 hour.  (See Table 4 for specific dilutions and sources.)   
After another 3 rinses, mounting medium with 4,6 diamidino-2-phenylindole (DAPI, 
Vector Laboratories, Burlingame, CA) was applied, slides were covered with a glass 
coverslip and sealed.   
 For preparation of cultured cells for confocal analysis, a similar procedure was 
followed except as noted here.  Cells grown on tissue culture dishes modified with glass 
bottoms were fixed with 4% paraformaldehyde after removal of neurobasal A growth 
media.  Fixed cells were rocked with primary antibodies overnight at 4˚C before 
decoration with secondary antibodies (See Table 4).   
Images were acquired on a Nikon Perfect Focus Ti-E confocal microscope and 
were analyzed on NIS Elements imaging software (Nikon Instruments, Melville, NY).   
To determine colocalization in slices, regions of interest (ROIs) were selected from areas 
within the stratum oriens, pyramidal cell layer, stratum radiatum, and dentate granule cell 
layer.  Prior to quantification, background fluorescence was removed by measuring 
brightness of each fluophore in preparations not treated with primary antibodies, then 
subtracting that brightness value from that of experimental slides.  The Pearson 
correlation coefficient (PCC) was determined for each region to quantify the degree of 
colocalization between Gαq and GABAB receptors in each region.  A higher PCC is 
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suggestive that proteins of interest are located in close proximity.  PCC values were 
averaged by region, then compared via one-way ANOVA.  When acquiring images to 
average and compare, microscope settings (scan speed, pinhole size, laser intensity) were 
not changed to allow for comparison across different preparations.   
 
Electrophysiology 
Calcium currents were measured using whole cell patch clamp electrophysiology 
in voltage clamp mode.  Currents were collected using a Dagan 3900A patch clamp 
amplifier (Dagan Corporation, Minneapolis, MN), Digidata 1322 data acquisition system, 
and pClamp 9.0/10.0 software (Molecular Devices, Sunnyvale, CA).  Recording 
immediately after dissociation minimizes space clamp problems, but in order to let the 
neurons recover from digestion and allow for sufficient knockdown, experiments were 
performed 24-48 hours after dissection.  A Flaming/Brown P-87 Micropipette Puller 
(Sutter Instrument Co, Novato, CA) was used to pull electrodes of 4-10 MΩ from 
borosilicate glass capillary tubes.  Pipettes were filled with internal solution (140 mM Cs-
aspartate, 5 mM MgCl2, 10 mM Cs2EGTA, 10 mM HEPES, 2 mM ATP-Na2, 0.1 mM 
GTP, pH 7.4 with CsOH and osmolarity of 310 – 320 mOsm); neurons were kept in 
extracellular solution (10 mM CaCl2, 145 mM TEACl, 10 mM HEPES, 1 µM 
tetrodotoxin (Tocris Bioscience, Bristol, United Kingdom), pH 7.4 with CsOH and 
osmolarity 300 – 310).  Whole cell currents were electronically filtered at 1 kHz and 
digitized at 2 kHz.  Linear components of leak current were subtracted post-hoc by the 
passive resistance protocol in the pClamp 9.0/10.0 software.  
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To study drug effects on maximally achieved calcium currents, neurons were 
depolarized for from -80 mV to +10 mV for 300 ms.  Analysis was performed during the 
last 50 ms of this pulse (the sustained component of the calcium current) to maximize the 
contribution of L-type (long 
lasting) current to total current 
(Figure 2.3).  However, it is 
likely that there is contribution 
from the other types of HVA 
currents (P/Q-type, N-type, R-
type), despite work showing that 
these channels inactivate much 
faster (τ = 50 – 80 ms versus τ > 
500 ms for L-type calcium 
current (Tsien et al., 1988).  In 
certain experiments, to reveal 
primarily L-type current, P/Q-
type and N-type current were blocked with application of 1 µM ω-conotoxin MVIIC 
(IC50 = 40 nM, (Gandia et al., 1997).  To examine the current-voltage relationship with 
and without baclofen, neurons were held at -80 mV and depolarized by a series of 10 mV 
steps from -50 mV to +50 mV.  For electrophysiological studies, various drugs were 
applied on the order of seconds via U-tube delivery system.  The U-tube was constructed 
of PE-10 polyethylene tubing housed in glass tubing, which allows for both rapid 
application and washout of pharmacological agents in an acute area.  Fast Green FCF 
Figure 2.3: (Top) Typical calcium current trace elicited, 
containing both a peak and sustained component. 
(Bottom) Depolarizing pulse given for 300 ms from -80 
to +10 mV. 
 
 
41 
 
(Sigma-Aldrich, St. Louis, MO) was added to the drug solution to visualize delivery.  
Table 5 contains concentrations of drugs used as well as their targets.                                                                                
The core of research done in the Mynlieff laboratory is understanding how 10 µM 
baclofen, a GABAB-specific agonist, enhances L-type calcium current.   Since calcium 
currents often demonstrate either run-up or run-down in their current, multiple control 
depolarizations were given whenever possible.  In order to characterize the response of 
neurons as either “increasing,” “decreasing,” or “no change” in their calcium currents, 
control pulses were given before application of baclofen, and again after washout.  
Control currents were plotted and a linear regression line was generated based on those 
controls, as well as a 95% confidence interval of this regression line.  Neurons treated 
with baclofen were categorized based on where they fell with respect to the 95%  
 
confidence interval. Furthermore, at any timepoint when pharmacological agents were 
applied, the linear regression equation allowed for calculation of an “expected” current 
Figure 2.4: 
Representative linear 
regression trace with 
95% confidence interval 
constructed.  In this case, 
treatment with the drug 
(red diamonds) leads to 
currents that fall outside 
the confidence interval 
constructed from control 
pulses (black circles), 
suggesting a significant 
effect of the drug. 
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(that which would be expected if the agent were not present). This could then be 
compared with actual current when the agent was present (Figure 2.4) 
Analysis of current-voltage (IV) data consisted of creating IV curves to describe 
L-type current at various voltages in either neurons treated with 10 µM baclofen or 
controls.  Conductance values were calculated at each voltage step by dividing peak 
current elicited by the driving force.  Driving force is the difference between the neuron’s 
membrane potential and the reversal potential for an ion.  It is defined by the equation 
Iion = gion(Vm – Eion), where Vm – Eion is the driving force. Conductance plots were 
generated to examine whether there was a shift in the activation voltage (voltage that 
causes channels to begin to open and current to be measured) or voltage that elicits half 
maximal current (V1/2) in those neurons treated with baclofen. 
  
Pharmacological 
Agent 
Source Concentration Pharmacological 
Activity 
IC50/EC50 
RS-Baclofen Sigma-
Aldrich 
10 μM Activate GABAB 
receptors 
2.8 μM 
ω-Conotoxin 
MVIIC 
Sigma-
Aldrich 
1 μM Block N- and P/Q-
type calcium 
channels 
40 nM 
Nimodipine Sigma-
Aldrich 
20 μM Block L-type 
calcium channels 
140 nM – 2.7 
μM 
Nifedipine Sigma-
Aldrich 
20 μM Block L-type 
calcium channels 
3 μM 
CamKIIntide EMD-
Millipore 
250 nM Inhibit CaMKII 
signaling 
50 nM 
Ant-AIP-2 EMD-
Millipore 
50 nM Inhibit CaMKII 
signaling 
4 nM 
CK59 EMD-
Millipore 
Various Inhibit CaMKII 
signaling; block 
voltage-gated 
calcium channels 
>10 μM for 
CaMKII; 52 
μM for 
calcium 
channels 
Table 5: Listing of pharmacological agents used in various studies 
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Protein knockdown with morpholinos 
In order to selectively knock down proteins of interest, morpholinos (Gene-Tools 
LLC, Philomath, OR) were used to prevent translation of mRNA.  Morpholinos (MO) are 
synthetic 25 amino acid-long oligos that are designed to bind near the start codon of 
specific mRNA.  This binding prevents association of the translational machinery to the 
mRNA, thus yielding decreased protein.  Morpholinos have several advantages over 
more traditional siRNA-mediated knockdown.  First, because they are synthetic, MO are 
not subject to enzymatic degradation that often break down siRNA over time.  Second, 
they achieve a highly specific knockdown, in contrast to siRNA mediated knockdown in 
which off target effects may occur.  Finally, successful siRNA mediated knockdown in 
primary neuronal cultures has proven more difficult than in other cell types.  Thus, the 
use of MO to achieve protein knockdown represents a viable and innovative alternative to 
more commonly used knockdown methods.    
 
 
 
 
Figure 2.5: Mopholinos penetrate the cell and prevent 
translation. (Right) The Endo Porter peptide binds the 
MO cargo and is taken into the cell in an endocytosis 
mediated process. (Top) Once inside, the MO binds to 
the targeted mRNA near the start codon, sterically 
inhibiting the initiation complex from associating, thus 
preventing translation of the mRNA.   
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Morpholinos were introduced to cell cultures immediately after plating.   In order 
for the cell to take up the MO, the MO were cotransfected with EndoPorter, a proprietary 
peptide that brings “cargo” into the neurons via an endocytosis-mediated process.  
Control experiments were done with a variety of EndoPorter concentrations (2-10 µM) to 
ensure there were no cytotoxic effects.  Delivery of MO was assessed using MO with a 
carboxyfluorescein tag fused to its 3’ end, then examined with fluorescent microscopy.  
The sequence of the morpholino designed to knock down Gαq was 5’ 
ACGCCATGATGGACTCCAGAGTCAT3’; it was delivered at a concentration of 2 µM 
together with 4 µM EndoPorter.  Because G-proteins are known to have a relatively long 
half-life (Derrien et al., 1996), Western blot experiments were done to assay knockdown 
at both 24 and 48 hours post transfection.  Control experiments were done on cell cultures 
treated with either a nonsense MO (5’ AGCCAACGCCCCAATGATTCTGACT3’) or 
cultures treated with EndoPorter only.   
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CHAPTER 3 
Demonstration of enhanced calcium entry upon GABAB receptor activation with 
ratiometric calcium imaging and examination of IV relationship in cells that do not 
demonstrate current enhancement 
INTRODUCTION 
During early neonatal development, neuronal GABA receptors have been 
extensively studied.  However, a large proportion of these studies involve the ionotropic 
GABAA receptor.  GABA is considered the main inhibitory neurotransmitter in the 
mature mammalian nervous system; when GABA binds to its GABAA receptor, the 
receptor passes negatively charged chloride ions inward.  This hyperpolarizes the neuron, 
and dampens excitability.  However, in the developing nervous system, the chloride 
gradient is reversed, and GABAA receptor activation will allow for chloride efflux.  
Negative charge is lost from the cell, and this depolarization increases the cell’s 
excitability (for review, see Ben-Ari 2002.  Thus, there have been a multitude of studies 
examining this switch in chloride currents and changes in GABAA receptor function 
(Hutcheon et al., 2000; Banks et al., 2002; Bray and Mynlieff 2009; Holter et al., 2010; 
Kilb 2012).  
The development of the metabotropic GABAB receptor is less well-defined.  
GABAB-mediated potassium currents can be consistently recorded after the first postnatal 
week (Gaiarsa et al., 1995), and protein expression reaches adult levels after the second 
postnatal week (Lopez-Bendito et al., 2004).  It has been suggested that GABAB 
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receptors do not undergo a major functional alteration during development (Kilb 2012).  
However work in the Mynlieff laboratory shows a potentially unique function of these 
receptors during the early neonatal period.  Activated GABAB receptors mediate both an 
increase and decrease in calcium current; furthermore, the increase in calcium current 
was through L-type calcium channels, while the decrease was through N-type calcium 
channels.  This inhibition has been previously described as occurring through N-type 
channels; the mechanism of inhibition has also been detailed. (Guyon and Leresche 1995; 
Harayama et al., 1998; Sun and Chiu 1999; Colecraft et al., 2000).  Conversely, when 
Carter and Mynlieff (2004) described the enhancement of L-type current in neonatal 
hippocampal cultures, there was only one report of GABAB receptors enhancing such 
current in neurons, in the salamander retina (Shen and Slaughter 1999).  Unlike the 
inhibition of N-type channels, the mechanism of this enhancement had not been clearly 
worked out.  Subsequent research in the Mynlieff laboratory revealed this enhancement 
to be a developmental phenomenon.  The proportion of neurons that demonstrate an 
increase in response to GABAB receptor activation increases until P7, then decreases at 
P14 (Bray and Mynlieff 2009).  Thus, data from the Mynlieff laboratory suggest there is 
a specific function of GABAB receptors during development. 
Understanding how neurons regulate calcium levels during development is 
critically important, as calcium is a crucial intracellular messenger.  Calcium influx can 
regulate neuronal differentiation, excitability, synapse formation, and gene transcription 
(for review see Lohmann 2009; Michaelsen and Lohmann 2010; Hagenston and Bading 
2011).  L-type current is thought to be more involved with these processes than with 
neurotransmission.  Therefore, deciphering the pathway by which GABAB receptor 
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activation leads to increased intracellular calcium concentrations during neonatal 
development may be critical in understanding how mature neuronal circuitry is 
established.  
  The focus of this study was to provide further detail of the interplay between 
GABAB receptors and L-type current.  Previous studies in the Mynlieff laboratory used 
whole-cell patch clamp electrophysiology to demonstrate L-type current enhancement 
and N-type current attenuation.  However, the throughput of electrophysiology is low, so 
I sought to elucidate details of the pathway using the higher throughput method of 
ratiometric calcium imaging.  Before examining any component of the GABAB receptor-
mediated response, it was necessary to demonstrate this phenomenon was not an artifact 
of electrophysiological recording.  Once calcium imaging was established as a viable 
method, the source of the calcium increase was investigated.  Calcium concentrations are 
kept at low levels inside the cell, relative to extracellular concentrations.  Calcium 
concentrations within the endoplasmic reticulum are high as well.  While it has been 
shown that calcium current increases upon GABAB receptor activation, the contribution 
of calcium released from intracellular stores (i.e. the endoplasmic reticulum) was not 
known.  Furthermore, in studies by Carter and Mynlieff (2004) and Bray and Mynlieff 
(2009, 2011), enhancement of L-type current always required depolarization to activate 
L-type channels.  However, a recent report showed activation of GABAB receptors alone 
was sufficient to increase intracellular calcium levels (Kuczewski et al., 2011).  I 
attempted to reproduce this effect to gain insight into a possible molecular mechanism for 
this enhancement.  Finally, since I also observed an attenuation of calcium entry in a 
subset of cells, I sought to characterize the kinetic changes occurring, similar to how 
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Carter and Mynlieff (2004) described the enhancing effect by examining the change in 
activation voltage and conductance shift.   
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RESULTS 
Ratiometric calcium imaging detects changes in intracellular calcium upon GABAB 
receptor activation 
 Previous studies in the Mynlieff laboratory have shown that cells treated with 10 
µM baclofen may show changes in calcium current when these cells are given a 
depolarizing pulse from -80 to +20 mV.  Cells showed a distribution of responses, where 
approximately 35% of neurons examined display attenuation of current, 25% of neurons 
display enhancement of current, and 40% of neurons do not display a significant effect on 
current.  In order to examine whether this phenomenon could be demonstrated using 
ratiometric calcium imaging, cells were loaded with a ratiometric dye (Fura-2 AM) for 1 
hour (see methods).  Instead of a depolarizing pulse, neurons were treated with a high (50 
mM) potassium chloride (KCl) solution to induce depolarization.  10 µM baclofen, a 
GABAB receptor-specific agonist, was preapplied for 15 seconds before the high KCl 
solution, as well as during the stimulation.  High KCl was perfused onto the cells first for 
thirty seconds.  After washout, baclofen and high KCl were coapplied.  Following a final 
washout KCl was applied once again.  The two high KCl alone values were averaged and 
compared with the middle (treatment) value. 
 Similar to electrophysiological data, calcium imaging data showed 3 distinct 
responses to baclofen treatment.  In initial studies, 25.7% of neurons showed increased 
calcium entry; the average increase was 25.0%, compared to baseline calcium entry when 
cells were depolarized with high KCl alone (not in the presence of baclofen).  48.0% of 
cells showed a decrease in calcium entry, with an average decrease of 23.6%.  Finally, 
26.3% of cells did not respond to baclofen treatment with either an increase or a decrease 
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in calcium entry.  These early studies considered an increase or a decrease to be ± 5% of 
control KCl values.  However, it became clear that there was greater inherent variability 
in response of control cells than the 5% cutoff being used.  Thus, cells were stimulated 
with high KCl three times.  The middle stimulation was considered the “treatment” and 
compared with the average of stimulations 1 and 3.  These data showed that KCl alone 
varied ± 10.7% from one KCl treatment to another (N = 127).  Therefore, using a 5% 
cutoff was not strict enough, and I could have been considering cells that varied based 
only on KCl treatment.  Experiments were repeated using a value of ± 21.4% (twice the 
standard deviation of the control response) to be considered increasing or decreasing, 
respectively.  As expected, the more stringent criteria changed the distribution of 
responses.  46 of 392 cells (11.73%) showed an increase in current entry, with an average 
increase of 39.29 ± 2.54% (Figure 3.1a).  106 (27.04%) cells showed a decrease in 
calcium entry, with an average decrease of 36.23 ± 0.96% (Figure 3.1b).  Finally, 240 
(61.22%) showed no change in calcium entry with the new, more stringent criteria 
applied (Figure 3.1c).  Though there were fewer cells that showed enhanced calcium 
entry upon GABAB receptor activation than when examined with electrophysiology, there 
was still a significant difference between controls and those treated with 10 µM baclofen.  
These results validated the electrophysiological studies and suggested ratiometric calcium 
imaging can be used as a tool to understand the activated GABAB receptor-mediated 
response.  
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Increasing intracellular calcium concentration is due to influx from the extracellular 
milieu 
To determine the proportion of calcium that enters the cell through surface 
calcium channels versus that which is released from intracellular stores, calcium imaging 
was used, and the concentration of calcium in the perfusing solutions was adjusted.  
Typically, the high KCl solution contains 10 mM calcium; when the cell is depolarized, 
there is a gradient which causes the ions to flow inward from outside the cell. However, 
the hypothesis of GABAB receptor activation is that it activates a pathway by which PIP2 
Figure 3.1: Response to baclofen and high KCl 
solution, as measured with ratiometric calcium 
imaging.  A: Neurons were depolarized with high 
KCL for 30 s, then baclofen was applied for 15 s 
before being coapplied for 30 s with high KCl.  A 
final high KCl treatment was performed after 
baclofen washout.  Representative traces of cells 
that show an increase in calcium entry as a 
response to treatment.  Each line represents an 
individual cell.  B: Same as A, only this subset of 
cells show a decrease in calcium entry.  C: 
Summary of cell responses, N = 342. 
A. 
B. 
C. 
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is cleaved.  One cleavage product, IP3 can translocate to the endoplasmic reticulum (ER) 
and activate IP3 receptors on the ER membrane.  These activated receptors are permeable 
to calcium, and thus the calcium sequestered in intracellular stores may be released.   
Therefore, high KCl solution was made with calcium absent.  When cells were stimulated 
for 30 seconds with 0 calcium-containing high KCl and baclofen, there was no detectable 
change (0.54 ± 2.59% increase) in intracellular calcium.  However, when the same cells 
were treated with 10 mM calcium-containing high KCl, the prototypical response (114 ± 
94.84% increase) was seen (N = 88, Figure 3.2 and Table 6).  These data suggest that the 
majority of calcium influx is through voltage-gated channels, rather than through release 
from intracellular stores.   
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: When high KCl is applied to open voltage-dependent channels but calcium is 
removed from the solution, no calcium entry is seen.   These data suggest that the source of 
calcium entry is from extracellular sources.  The response is restored when calcium is added 
back to the depolarizing solution and the rinsing solution. 
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Given that 10 µM baclofen did not cause an increase in intracellular calcium 
when no calcium was present in the extracellular solution and voltage-gated channels 
were open, it seemed unlikely that stimulation of GABAB receptors without 
depolarization would lead to change in intracellular calcium.  However, it has been 
reported that increased concentrations (50 µM) of baclofen were sufficient to induce an 
increase in intracellular calcium in P0 hippocampal cultures (Kuczewski et al., 2011), 
thought to be caused by the pathway mentioned above.  I used the same 50 µM 
concentration of baclofen and attempted to replicate these data; cells treated with KCl 
alone averaged a 144 ± 90.16% increase in intracellular calcium compared to baseline 
levels. The same cells averaged a 1.95 ± 4.74% change when 50 µM baclofen was 
applied (N = 68, Table 7).  This result agrees with the data mentioned previously, that 
changes in intracellular calcium require opening of voltage-gated channels and 
extracellular calcium to be present.  Furthermore, activation of GABAB receptors alone, 
even at high concentrations, cannot induce a change in intracellular calcium.   
 
 
 
Treatment Baseline 
340/380 
Ratio 
Peak 
340/380 
Ratio 
% change 
50 mM KCl 0.42 ± 0.10 0.88 ± 0.35 114.74 ± 94.84 
50 mM KCl with 0 mM Ca2+, 
10 µM Baclofen 
 
0.44 ± 0.11 
 
0.44 ± 0.10 
 
0.54 ± 2.59 
Table 6: Summary of cellular responses when depolarized with high KCl with or without 
calcium present in solutions. Data represent mean ± SEM. 
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Attenuation of calcium current does not shift activation voltage or conductance of 
calcium channels 
 While much of the focus of my work has been to detail mechanisms responsible 
for the enhancement of intracellular calcium upon GABAB receptor activation, there is a 
proportion of neurons that undergoes a reduction of intracellular calcium under the same 
conditions.  The inhibitory response seen when baclofen is applied can be abolished by 
ω-conotoxin GVIA, suggesting it is specifically N-type channels that are inhibited (Carter 
and Mynlieff 2004).  A more detailed kinetic analysis was performed on the neurons that 
demonstrated current enhancement, which showed that GABAB receptor-mediated 
increases in L-type current caused a decrease in the voltage at which the L-type channel 
begins to pass current, as well as a leftward shift in the conductance.  This study did not 
examine similar parameters of N-type inhibition.  When N-type channels were inhibited 
by G protein-coupled δ-opioid receptor activation or by neurotransmitters norepinephrine 
and somatostatin, inhibition was mediated through a slowing of activation kinetics; the 
peak component of the current developed significantly slower than controls (Golard and 
Siegelbaum 1993; Toselli et al., 1999).  GABAB-mediated N-type inhibition has been 
examined, and similar to N-type inhibition in other systems, voltage-dependent inhibition 
develops due to a slowed activation phase of the peak current (Tatebayashi and Ogata 
1992).  However, none of these studies examined whether the activation voltage of these 
Treatment Baseline 340/380 
ratio 
Peak 340/380 ratio % change 
50 mM KCl 0.31 ± 0.04 0.79 ± 0.37 144.32 ± 90.16 
50 µM Baclofen 0.31 ± 0.05 0.32 ± 0.05 1.95 ± 4.74 
Table 7: Summary of responses seen in cells depolarized with high KCl, or treated with GABAB 
agonist baclofen alone 
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calcium channels were affected.  Thus, the focus of this study was to examine whether N-
type inhibition shifted activation voltage such that a stronger depolarization is required to 
pass current.   
To determine whether activation voltage is shifted in cells that demonstrate 
attenuation of calcium current, neurons were held at -80 mV.  Pulses 300 ms in duration 
were given from -50 mV to +50 mV in 10 mV steps.  10 µM baclofen was applied after 
control currents were elicited.  After currents were measured in the presence of baclofen, 
the drug was washed out and another group of currents was collected.  Since cell cultures 
contain a heterogeneous mix of neurons, each cell has a different array of voltage-gated 
calcium channel types.  However, the maximal activation voltage of these currents was 
always between +10 mV and +20 mV.  In order to determine a cell’s response to baclofen 
treatment, peak current was measured at +20 mV in the presence and absence of 
baclofen, as well as after washout.  A linear regression line of control values was 
constructed, to account for run up or run down commonly seen with calcium channel 
recordings.  A 95% confidence interval was constructed, and the experimental value  
 
 
 
 
 
 
 
Figure 3.3: Linear regression 
line constructed from control 
300 ms depolarizing pulses 
(black dots) surrounded by 
95% confidence interval.  
Baclofen application (red 
diamond) is outside the 
confidence interval and is 
therefore considered as 
having a significant effect.  
Inset: raw trace containing 
values used to construct linear 
regression line.  Blue line: 
control; red line: baclofen 
application; black line: 
washout. 
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plotted.  If the experimental value was below the linear regression line and outside the 
confidence interval, it was considered to show attenuation of current (Figure 3.3).   
Full current-voltage (IV) relationships of neurons that showed this reduction of 
current or those that showed no change (experimental fell within the 95% confidence 
interval) were constructed (Figure 3.4).  The voltage at which channels begin to display 
current was derived from these measurements.  Furthermore, conductance values were 
calculated by dividing peak current by the driving force.  Conductance plots were 
constructed and the voltage was measured when the neuron reached half-maximal 
conductance (V1/2).  The V1/2 for cells that do not show a difference in calcium current 
when GABAB receptors are activated is 8.3 ± 1.4 mV, compared to 8.2 ± 1.2 mV in 
controls (N = 15).  The V1/2 for cells that display attenuation of calcium current is 9.8 
mV, compared to 8.5 mV in controls (N = 2, Figure 3.5).  Baclofen application did not 
significantly shift a cell’s activation voltage compared to its value before or after 
treatment.  These data suggest N-type channel inhibition is not due to a change in 
activation voltage or whole cell conductance; more likely it is the slowed activation phase  
 
Figure 3.4: Current-voltage 
(IV) relationship in a neuron 
that demonstrates attenuation 
of current when treated with 
baclofen.  The peak component 
of calcium current was 
measured during the 300 ms 
depolarizing pulse.  The cell 
was held at -80 mV, and 
voltages were increased +10 
mv from -50 to +50 mv.  There 
is no shift in the IV curve when 
current is attenuated (red trace).  
Voltage (mV) 
C
u
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A
) 
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and voltage-dependent inhibition suggested by Tatebayashi and Ogata (1992).   
 
 
 
 
 
 
 
 
 
  
Figure 3.5: Activation curve of peak 
current in a neuron that demonstrates a 
decrease in response to baclofen 
application.  Data were fit with a 3-
parameter sigmoidal equation.  
Conductances were normalized at each 
test potential by dividing the 
conductance at each test potential by 
the maximal conductance obtained for 
that cell. Half-maximal activation 
voltage (V1/2) was calculated for each 
individual cell. 
58 
 
DISCUSSION 
GABAB receptor-mediated enhancement of L-type current was a phenomenon 
first described with the use of electrophysiology (Shen and Slaughter 1999).  Since then, 
the Mynlieff laboratory has confirmed this finding in the developing mammalian system, 
also using electrophysiology (Carter and Mynlieff 2004; Bray and Mynlieff 2009; Bray 
and Mynlieff 2011).  However, while electrophysiology can provide much faster 
temporal resolution, its throughput is limited.  Thus I showed that calcium imaging can 
similarly be used to demonstrate this effect.  It is important to note that calcium imaging 
does not measure calcium current directly; instead it measures a difference in fluorescent 
states of a specific fluorophore.  The key to ratiometric imaging is that by using a dual 
wavelength fluorophore, not all cells are required to take up exactly the same 
concentration.  For example, Fura-2 AM is excited at 340 nm when not bound to calcium; 
in its bound state, it is excited at 380 nm.  Thus, the response of changing levels of 
fluorescence is simply a difference in ratio between free Fura-2 AM and Fura-2 AM 
bound to calcium in any given cell.  As calcium enters, more calcium becomes bound by 
the Fura-2 AM, such that a change in fluorescence is actually a change in ratio 340 to 380 
ratio; this serves as an indirect measure of calcium entry. Another concern regarding 
fluorescence measurements is that since the volumes within individual neurons in culture 
is unequal, one is only capturing data on a specific plane.  If the plane is not the same, 
light intensity may vary from one compartment to the other.  Using a dual length 
fluorophore like Fura-2 AM alleviates this issue.  For example, a neuronal cell body may 
be more round, and its associated dendrite will be relatively flatter.  Since the ratiometric 
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imaging is always comparing bound to free Fura-2 AM, any region of interest will always 
be compared to itself, dendrite to dentrite, or cell body to cell body. 
It is also likely that calcium imaging does not have as much experimental bias as 
does electrophysiology.  When performing calcium imaging, all cells are examined, 
regardless of size, morphology, etc.  Only if they are unhealthy are they not included in 
data analysis.  For example, a cell whose calcium levels do not return to baseline after 
high KCl is washed out will not be included in analysis, because it is likely not healthy 
enough to extrude calcium.  Electrophysiological recording allows the experimenter to 
pick the cells from which he or she records.  This artificial selection may not reflect the 
actual makeup of cells in culture.  One concern of data presented here is that the 
proportion of cells that demonstrate enhancement of calcium entry is approximately half 
of that seen in electrophysiology.  This is likely due to experimental bias.  Because 
calcium imaging is likely a better representation of the all cell types in the culture, it is 
possible that enhancement measured here is more accurate than what is observed with 
other methods.  Thus, while calcium imaging does not provide the fast temporal 
resolution of whole cell patch clamp recording, it has numerous advantages and can be 
used to show similar effects as electrophysiology.  
Our laboratory and others that GABAB receptor activation can lead to increased 
levels of intracellular calcium (Shen and Slaughter 1999; Carter and Mynlieff 2004; Bray 
and Mynlieff 2009; Bray and Mynlieff 2011; Park et al., 2010; Kuczewski et al., 2011; 
Mitzuta et al., 2011; Im and Rhim 2012).  However, despite this phenomenon being 
described several times, the mechanism responsible for enhanced calcium levels remain 
unknown.  One hypothesis is that the behavior of the channel is modified, such that it 
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passes more current.  An example of this possibility is that phosphorylation of the 
channel could lead to its being open for longer periods of time.  A second hypothesis is 
that activation of GABAB receptors leads to activation of PLCβ, generation of IP3 after 
cleavage of PIP2, and opening of calcium-permeable IP3 receptors on the endoplasmic 
reticulum.  If this hypothesis is correct, activation of GABAB receptors alone should 
induce increases in intracellular calcium levels.  However, data presented here show 
applications of GABAB agonist baclofen resulted in no change in intracellular calcium 
levels when cells were not depolarized.  When calcium channels were activated but no 
calcium was present extracellularly, baclofen still failed to cause an increase in 
intracellular calcium levels.  These data are in agreement with previous data in the lab 
that enhanced calcium concentration is through L-type calcium channels.  Kuczewski et 
al., (2011) was able to block baclofen mediated calcium enhancement by inhibiting L-
type channels.  This is particularly interesting because in this study, cells were never 
depolarized, suggesting some novel mechanism whereby L-type channels are activated 
by the GABAB response.  Perhaps a more plausible scenario is that activation of GABAB 
receptors initiates a signal transduction cascade that leads to modulation of L-type 
channels, such that they can allow more calcium into the cell.  This hypothesis is 
supported by data from Carter and Mynlieff (2004) which shows that L-channels activate 
at more hyperpolarized potentials in the presence of baclofen.  It is possible that other 
kinetic changes underlie observed enhancement as well.  Changes in open probability or 
mean open time of the channels due to a phosphorylation event could lead to increased 
concentrations of calcium; single channel recording would be required to examine this 
hypothesis.   
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In addition to observing enhancement of calcium entry when performing calcium 
imaging, a subset of cells also demonstrated reduced calcium entry.  This finding was 
previously demonstrated in our laboratory, and characterized pharmacologically as 
inhibition of N-type calcium channels (Carter and Mynlieff 2004).  I conducted studies 
that characterized the current-voltage relationship of neurons that demonstrate attenuation 
of N-type current, as well as those neurons whose current is not changed.  The purpose 
was to examine whether these cells displayed a shift that may help explain how baclofen 
affects calcium channels.  Not surprisingly, I found there is no change in activation 
voltage or V1/2.  The closely related P/Q-type channel is similarly inhibited by GABAB 
receptor activation, by the same mechanism as N-type channels.  When the IV curve for 
P/Q-channel inhibition is shown, activation voltage does not change (Mintz and Bean 
1993).  Furthermore findings by (Carter 2002) showed only a slight leftward shift in the 
IV curve of cells that showed attenuation when exposed to baclofen; there was no 
significant difference in the activation voltage of these cells.  My work essentially 
repeated these studies and led to the same conclusion.  The most plausible hypothesis is 
that current develops more slowly due to the slowed activation phase of the N-type 
channel and characteristic voltage-dependent inhibition of these channels (Tatebayashi 
and Ogata 1992).   
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CHAPTER 4 
The signaling pathway involved in GABAB receptor activation-mediated  
increases in L-type calcium current 
INTRODUCTION 
 GABAB receptor activation is most commonly linked to a response that decreases 
a neuron’s excitability.  Upon ligand binding, there are three well described inhibitory 
mechanisms.  First is inhibition of voltage gated N- and P/Q-type calcium channels.  
Presynaptic inhibition leads to decreased release of neurotransmitter, while postsynaptic 
inhibition decreases dendritic calcium spikes.  Second is activation of GIRK channels.  
When GIRK channels are active, potassium ions move out of the neuron, generating slow 
inhibitory postsynaptic potentials (IPSPs).  Finally, GABAB activation decreases 
phosphorylation of target proteins due to reduced protein kinase A (PKA) activity.  The 
G protein α subunit mediates the decrease in PKA activity through a signal transduction 
cascade; adenylate cyclase is inhibited from producing cyclic AMP (cAMP).  Without 
cAMP, PKA remains catalytically inactive.  It is the G protein βγ subunits which mediate 
the decrease in N- and P-Q current as well as GIRK current.  Importantly, whether it is 
the α or βγ subunits which decrease excitability, GABAB receptors have always been 
linked with Gαi/o G proteins.   
 A less well described phenomenon is the enhancement of L-type calcium current 
upon GABAB receptor activation.  This GABAB mediated increase in L-type current has 
been suggested to be a means by which GABAA receptors get inserted into membranes; 
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increased L-type current causes secretion of brain-derived neurotrophic factor (BDNF), 
which has been shown to modulate GABAA expression previously (Kuczewski et al., 
2011).  GABAB receptor-induced increases in L-type current also increase 
phosphorylation levels of extracellular signal-regulated protein kinase 1/2 (ERK1/2, Im 
and Rhim 2012).  ERK1/2 is known to activate cAMP response element binding protein 
(CREB, Vanhoose et al., 2002; Tu et al., 2007) as well as be involved in synaptic 
plasticity (Giovannini 2006).  However, while it has been shown that GABAB receptor 
activation can lead to ERK1/2 activation, the targets of this activated ERK1/2 remain 
unknown. 
 While there are few reports of GABAB receptor mediated increases in activity, 
there is even less known about the signaling cascade that promotes current enhancement.  
Initially, Shen and Slaughter (1999) described this enhancement as sensitive to protein 
kinase C (PKC) inhibition, and somewhat less sensitive to protein kinase A (PKA) 
inhibition.  Furthermore, enhancement could be abolished by treatment with 
dihydropyridines, verifying L-current was being affected (Shen and Slaughter 1999; 
Carter and Mynlieff 2004).  More recent work in our laboratory showed that, when 
treated with pertussis toxin to inhibit Gαi/o protein signaling, enhancement persisted (Bray 
and Mynlieff 2011).  These data suggested that GABAB receptors couple to a G protein 
besides the canonical Gαi/o to produce enhancement.  
 A large portion of my work was to determine the signaling cascade that resulted 
when GABAB receptors were activated.  Since Gαi/o G proteins were likely not involved, 
it was hypothesized that GABAB receptors may couple promiscuously to more than one 
G protein.  The involvement of PKC suggested that Gαq was responsible for the observed 
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current enhancement, since Gαq activation has been demonstrated to activate 
phospholipase C (PLC), which increases PKC activation.  In order to test this hypothesis, 
I employed a strategy of morpholino (MO)-induced knockdown.  Furthermore, while 
PKC has been demonstrated to be a requisite member of the signal transduction pathway, 
the isoform had not been identified.  When cells were treated with PKC activator phorbol 
12-myristate 13-acetate (PMA), a phorbol ester, enhancement of calcium current could be 
reproduced (Bray and Mynlieff 2011).  Because only a subset of PKC isozymes are 
sensitive to phorbol stimulation, and because the enhancing effect is maximally observed 
at P7, it narrowed the possible candidates to three isozymes, α, β, and ε.  Finally, it was 
hypothesized that calcium/calmodulin-dependent kinase II (CaMKII) was involved in this 
pathway, because a report from O-Uchi et al. (2008) showed that cardiac myocytes 
demonstrate enhanced L-type current as a result of Gαq signaling, also mediated by PKC 
and CaMKII.   
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RESULTS 
Mopholino oligos effectively enter mammalian neurons grown in culture 
In order to examine whether GABAB receptors exert their effects through 
signaling the α subunit of the Gαq G protein complex, I employed the strategy of 
knockdown via morpholino (MO) oligonucleotides. MO are synthetic oligos designed to 
bind target mRNA and inhibit their translation.  They are readily taken up by cells in 
culture, and fused to a 3’ carboxyfluorescein molecule to visualize delivery into the cell 
(figure 4.1a and b).   
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Introduction of morpholino (MO) oligos and their effect on cultured hippocampal 
neurons.  A) Differential interference contrast image of a hippocampal culture from P4 rat pups 
treated with 10 µM control oligos and 2 µM Endo-Porter peptide, maintained in culture for 96 
hours.  B) Fluorescent image of cells pictured in A; MO were tagged with carboxyfluorescein 
for visualization and assessment of delivery.  C) Western blot of proteins isolated from either 
control cultures (lane 1), cultures treated for 24 or 48 hours with 2 µM Gαq MO and 4 µM 
Endo-Porter (lanes 2 and 3, respectively).  These cultures were obtained from P6-8 rats.  The 
Western blot was decorated with Gαq antibodies and β-tubulin antibodies as a loading control 
D) Quantification of Gαq band density.  Values were calculated by dividing integrated optical 
density (IOD) of the Gαq band by the IOD of the β-tubulin band to control for sample loading.  
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While this strategy is common in zebrafish, there are fewer reports of their 
successful use in mammalian neurons. Before proceeding with knockdown of Gαq, it was 
necessary to verify that MO were able to be taken up by mammalian cells and were non-
toxic.  Cultures were treated with Endo-Porter, a proprietary molecule that causes 
endocytosis-mediated uptake of cargo (see Chapter 2 for figure), and a nonsense MO 
(one that did not bind to any known mRNA) and visualized after 24, 48, and 96 hours of 
incubation.  Figure 4.1 shows cultures after 96 hour treatment.  Cells appear healthy, 
displaying growing processes and maintaining their characteristic shape.  When 
examined under fluorescence, every cell displays some level of fluorescence, suggesting 
universal uptake of the MO oligos.  At concentrations ≥ 4 µM oligos or ≥ 6 µM Endo-
Porter, treatment with MO began to negatively affect growth and viability of neuronal 
cultures (data not shown).  Thus, 2 µM MO and 4 µM Endo-Porter were used.   
 
Morpholino oligos effectively inhibit translation of Gαq 
 To determine the effectiveness of MO-induced protein knockdown, neurons were 
treated with Endo-Porter alone, Endo-Porter and nonsense oligos, or Endo-Porter and 
MO against Gαq G protein.  Western blotting was performed either 24 or 48 hours after 
treatment.  Figure 4.1c shows that after 24 hours, significant knockdown was achieved.  
G proteins have relatively long half-lives, up to 30 hours (Derrien et al., 1996); thus MO 
were added to cell cultures for 48 hours to maximize knockdown.  48 hour treatment 
almost completely abolished the Gαq protein signal. Cultures treated with Endo-Porter 
alone or nonsense MO demonstrated comparable levels of Gαq protein expression as 
controls (data not shown).  Thus, using the Endo-Porter delivery system, Gαq protein 
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expression in neuronal cultures was reduced without negatively impacting cell health or 
viability, determined both physiologically (by observing characteristic intracellular 
calcium increases upon depolarization) and morphologically.  Due to the relatively long 
half-life of G proteins, all electrophysiological and calcium imaging experiments were 
performed following 48 hour incubation with Gαq to ensure the highest degree of protein 
knockdown possible.  
 
Gαq is more highly expressed than Gα11 in the neonatal hippocampus 
 Gα11 shares 90% sequence similarity with Gαq and both proteins have a 
ubiquitous distribution pattern (Mizuno and Itoh 2009).  Therefore, it was important to 
determine whether there could be nonspecificity in the MO knockdown of Gαq that may 
decrease expression of Gα11 as well.  Protein preparations from cultured cells were 
treated with either Gαq or nonsense MO and analyzed by Western blotting using Gα11 
antibodies.  If the MO were specific to Gαq, there would be no change in the expression 
of Gα11.  However, no signal was detected in these preparations, or in control 
preparations not treated with MO, nor those only treated with Endo-Porter (data not 
shown).  This result was suggestive that either the basal level of Gα11 was too low to 
detect with Western blotting in preparations of cultured neurons, or the Gα11 antibody did 
not recognize its target.  To determine whether the Gα11 antibody could recognize Gα11 G 
protein, protein samples were prepared from the superior region of the hippocampus so 
that the amount of protein loaded on a gel could be increased.  Antibodies to Gαq and 
Gα11 detected proteins of similar weights as expected.  Figure 4.2 shows that the Gα11 
antibody does recognize its target, but only if 5-10 times the amount of protein was  
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loaded and the decorated membrane was exposed to film for a longer period of time.  
When a lane loaded with 2 µg of protein was probed with Gαq antibody, the integrated 
optical density (IOD) was 7.2.  When a lane was loaded with 20 µg of protein and probed 
with Gα11 antibody, the IOD was 5.0, on the same film with the same exposure time.  
These data suggest that Gαq expression is likely 10-fold or more higher than that of Gα11.  
With such a small basal level of Gα11 expressed, it is not surprising that this protein was 
undetectable in Western blots loaded with cultured cell preparations.  Expression data 
here supports a similar previous finding that Gαq is more highly expressed than Gα11 in 
hippocampal tissue.   
 
Inhibiting Gαq expression abolishes baclofen-mediated voltage gated calcium 
current enhancement 
 Previous studies showed that the enhancing effect of GABAB receptor activation 
on L-type current was not mediated by a Gαi/o G protein, because  pertussis toxin (PTX) 
Figure 4.2: Expression levels of Gαq and 
Gα11 in the superior region of the 
neonatal rat hippocampus.  Western blot 
analyses were performed on samples 
using antibodies against Gαq or Gα11.  
Lanes 1-4 (middle panel) were loaded 
with 10 times less protein than lanes 5-7.  
In order to visualize bands probed with 
Gα11 antibody, exposure time was 
increased to 10 minutes (right panel), 
compared to 3 minute exposure used to 
visualize bands probed with Gαq.  The 
left panel shows markers used for 
molecular weight calculations. 
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treatment eliminated only attenuation of calcium current, while enhancement persisted in 
PTX-treated populations of neuronal cultures (Bray and Mynlieff 2011).  Despite a lack 
of precedence for GABAB receptor coupling to Gαq, downstream actions, including PKC 
activation, were consistent with the actions of a Gαq G protein family member.  
Therefore, we chose to knock down Gαq and assess whether application of the GABAB 
receptor agonist baclofen (10 µM) could still lead to L-type current enhancement.  
Hippocampal cultures treated with either nonsense or Gαq MO were stimulated with a 
high KCl solution, followed by a high KCl solution containing 10 µM baclofen, and 
assessed with ratiometric calcium imaging.  In nonsense MO-treated cells, 6 out of 64 
cells (9.37%) demonstrated enhancement of calcium entry when baclofen was coapplied 
with high KCl (Figure 4.4b).  This percentage is not statistically different than the 
percentage of cells showing enhancement treated with only 10 µM baclofen and no 
morpholinos.  Conversely, none of the 207 cells treated with Gαq morpholinos 
demonstrated enhancement of calcium entry when baclofen was coapplied with KCl 
(Figure 4.4d, Chi square, P < 0.001).  Notably, 56 of the 207 cells (27.05%) still 
demonstrated inhibition of calcium entry, suggesting that Gαi/o-mediated inhibition of 
channels was unaffected (data not shown).  To verify the result that knockdown of Gαq 
resulted in elimination of calcium current enhancement, whole-cell voltage clamp 
electrophysiology was used.  In control cells treated with nonsense MO, 3 out of 25 cells 
demonstrated an enhancement of calcium current when baclofen was applied and cells 
were depolarized to +10 mV for 300 ms (Figure 4.4a).  In contrast, 0 out of 16 cells 
treated with Gαq MO for 48 hours demonstrated enhancement of calcium current under 
the same experimental conditions (Figure 4.4b).  Though these electrophysiological 
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results failed to reach statistical significance, they follow the same pattern as the highly 
significant calcium imaging data.  Taken together, these sets of experiments demonstrate 
that knockdown of Gαq G proteins abolished enhancement of calcium current or entry 
upon GABAB receptor activation, linking a Gαq family member to this pathway and thus 
the GABAB receptor itself.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Effect of 48 hour treatment with Gαq MO on calcium entry in hippocampal neurons.  
Neurons were treated with either nonsense MO (A and C) or Gαq MO (B and D).  Voltage gated 
calcium currents were elicited by a 300 ms depolarizing pulse to +10 mV from a holding 
potential of -80 mV in the absence (green trace) and presence of 10 µM baclofen (red trace; A 
and B).  Increases in intracellular calcium were induced by high KCl solution-mediated 
depolarization were measured with ratiometric calcium imaging as the ration of the intensity 
when excited by 340 nm light over the intensity when excited by 380 nm light (C and D).  Each 
colored line in C and D represents a single cell.   
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GABAB receptors colocalize with Gαq G proteins 
To further examine the possibility that GABAB receptors couple to G proteins, 
confocal imaging was used to determine whether these two proteins colocalize.  
Hippocampi were frozen and sliced into 20 µM sections, which were decorated with 
primary antibodies against GABABR1 and Gαq.  When sections were labeled with 
antibodies against GABAB receptors (red), nearly all areas were labeled, with the 
exception of the granule cells in the dentate gyrus.  Labeling was most intense in the 
pyramidal cell layer and the region containing the mossy fibers; lighter labeling was also 
evident in the stratum oriens and stratum radiatum.  At high magnification, there was a 
total absence of nuclear labeling with GABAB receptor antibodies, and a clear delineation 
between the nuclei and the cytoplasm.  Antibodies against Gαq labeled cells within both 
the pyramidal layer and the granule cell later.  In addition, there appeared to be individual 
cell bodies labeled within the stratum oriens and stratum radiatum without any diffuse 
labeling throughout these layers, as seen with GABAB receptor antibodies.  At low 
magnification, colocalization of the two fluorophores was most evident in the pyramidal 
cell layer and was absent from the dentate gyrus granule cell layer.  Quantitative analysis 
done at high magnification in the superior region of the hippocampus supports qualitative 
evidence seen at low magnification.  The average Pearson’s Correlation Coefficient 
(PCC), used to determine colocalization, was 0.125 ± 0.03 (S.E.M.) in the stratum oriens.  
The PCC was 0.476 ± 0.03 in the pyramidal cell layer and 0.102 ± 0.01 in the stratum 
radiatum.  The colocalization of GABAB receptors and Gαq is highest in the pyramidal 
cell layer, as suggested by the PCC value; the PCC is significantly higher in the 
pyramidal cell layer than either the stratum radiatum or stratum oriens (P < 0.001).  The 
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radiatum and oriens are not significantly different from each other (One way ANOVA 
followed by Holm Sidak pairwise comparison).  It should be noted that a small number of 
neurons in the stratum radiatum and stratum oriens were labeled by antibodies against 
Figure 4.4: GABAB receptors colocalize with Gαq G proteins in rat hippocampus.  Hippocampal 
sections were labeled with ployclonal rabbit anti-GNAQ and monoclonal mouse anti GABABR1 
followed by Dylight® 488-conjugated goat-anti rabbit IgG (green) and Dylight® 550-
conjugated goat-anti mouse IgG (red) for visualization.  Nuclei were stained blue with DAPI.  
Colocalization of the red and green fluophores appears yellow in the merged images of (C, D, 
G, H, and I)  White arrowheads in (C) indicate the colocalization seen in the pyramidal cell layer 
but not the dentate granule cell layer.  Images in (A,B, E, and F) represent the proteins of interest 
in isolation with the images merged in column 3 and nuclear staining (blue) added in column 4.  
A-D: Low magnification image showing the whole section of hippocampus.  E-H: High 
magnification image showing the pyramidal cell layer, the stratum oriens, and the stratum 
radiatum.  I: A small number of cells in both the stratum oriens and the stratum radiatum 
appeared to show colocalization of GABAB and Gαq with a high PCC value.  One of these cells 
in the radiatum is shown with a white arrowhead.  J: Control sections were stained without 
primary antibodies to ensure specificity.  Red blood vessels can be seen due to autofluorescence.  
Abbreviations: DG dentate gyrus, R stratum radiatum, P pyramidal cell later, O stratum oriens. 
Scale bar = 10 µM.    
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Gαq, and some of these neurons also appeared to be labeled with GABAB receptor 
antibodies.  Indeed, these neurons had a relatively high (0.5 – 0.75) PCC value.  The 
functional significance or physiological identity of these neurons is unknown.   
 
CaMKII activity is not involved in GABAB receptor-mediated increases in 
intracellular calcium 
 PKC activity has been shown to be required in the signal transduction pathway 
beginning with GABAB receptor activation and ultimately resulting in increased calcium 
current (Bray and Mynlieff 2011).   Recently, O-Uchi and colleagues described α1A-
adrenoreceptor coupling to Gαq/11 to activate PKC, leading to an increase in L-type 
calcium current in cardiac myocytes (2008).  Importantly, this study showed that CaMKII 
was a member of this pathway as well, because inhibition of CaMKII could abolish the 
enhancement of L-type current.  PKC has been shown to phosphorylate CaMKII, and 
because L-type channels are known to be phosphorylated by CaMKII, the involvement of 
CaMKII in the activated GABAB receptor pathway was investigated.  Cultured neurons 
were depolarized with a high KCl solution, followed by a high KCl solution containing 
both 10 µM baclofen and a cell-permeable CaMKII inhibitor Ant-AIP-II (50 nM, IC50 = 4 
nM).  Both baclofen and Ant-AIP-II were coapplied during a 15 second pretreatment 
period as well as during the high KCl application.  This length of time has been 
demonstrated to be sufficient for inhibition of CaMKII (Aromolaran and Blatter 2005).  
22 of 255 (8.63%) of cells continued to demonstrate increased calcium entry, despite the 
presence of the CaMKII inhibitor (Figure 4.5a).  When the inhibitor/baclofen solution 
was washed off, the response returned to original levels.  Because there have been reports 
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of nonspecific actions of CaMKII inhibitors on calcium channels (Gao et al., 2006; Karls 
and Mynlieff 2013), the result was confirmed using a second cell permeable inhibitor, 
CamKIINtide (IINtide, 250 nM, IC50 = 50 nM).  A similar result was obtained where 47 
of 432 (10.88%) neurons showed a reversible increase in calcium entry when baclofen 
was coapplied with IINtide (Figure 4.5b).  These values are not significantly different 
from control cells treated with baclofen alone, where 46 of 392 (11.73%) of cells show 
increased calcium entry when treated with high KCl. (Figure 4.5c, Chi square).   
 
 
  
 
 
 
 
 
 
 
Figure 4.5: The increase in calcium entry due to GABAB receptor activation with baclofen is not 
affected by CaMKII inhibitors. Each colored line in A and B represents a single cell. A: 
Enhancement of the 340 to 380 ratio persists, despite the presence of CaMKII inhibitor Ant-AIP-
II (50 nM). The enhancement is reversible, shown by the washout of baclofen and Ant-AIP-II. B: 
Enhancement of the 340 to 380 ratio persists, despite the presence of CaMKII inhibitor IINtide 
(250 nM). The enhancement is reversible, shown by the washout of baclofen and IINtide. C: 
Summary of the baclofen-mediated increase in the 340 to 380 ratio. There is no significant 
difference in number of cells demonstrating this increase in controls treated with only baclofen 
versus treatment with baclofen and Ant-AIP-II, or treatment with IINtide (Chi square). Total N 
inset in each bar. D: Electrophysiological recording elicited by a 300 ms test pulse from a holding 
potential of -80 mV to +10 mV shows persistent calcium current enhancement when baclofen and 
Ant-AIP-II are present (red line) compared to a control pulse (green line). 
 
 
+ 
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In addition to calcium imaging, electrophysiological recordings were performed 
in the presence and absence of 50 nM Ant-AIP-II and 10 µM baclofen.  Cells were 
depolarized to +10 mV from a holding potential of -80 mV to establish a baseline 
calcium current measurement.  Addition of Ant-AIP-II with baclofen did not affect the 
enhancement of calcium current characteristically displayed in a subset of cells in 
response to baclofen alone.  In these experiments, 4 of 23 (17.39%) of cells treated with 
Ant-AIP-II and baclofen displayed a significant increase in calcium current (Figure 4.5d).  
Thus, since neither inhibitor blocked enhancement of intracellular calcium in two 
different paradigms, it is likely that CaMKII is not involved in the GABAB receptor-
mediated enhancement of L-type current.  
 
PKCα translocates to the membrane upon GABAB receptor activation 
A previous study demonstrated that activation of PKC by phorbol esters 
mimicked the effect of GABAB receptor stimulation on calcium currents in cultured 
hippocampal neurons (Bray and Mynlieff 2011).  Therefore, only phorbol ester sensitive 
isozymes of PKC that are expressed in the early neonatal period were tested (Tanaka and 
Nishizuka 1994; Roisin and Barbin 1997).  Recent experiments by Mynlieff analyzed 
immunohistochemical images with confocal microscopy to determine whether PKCα, 
PKCβ, or PKCε translocated from the cytosol to the plasma membrane after 10 minutes 
of baclofen treatment (Figure 4.6a and b).  For each experiment, two different control 
conditions were run in parallel with the dishes treated with baclofen.  Cells were either 
treated with no drugs (unstimulated) or with the phorbol ester, phorbol 12-myristate 13-
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acetate (PMA, 1 µM) to verify that the translocation to the membrane was visually 
apparent in confocal images.  Both treatment with PMA and baclofen caused 
translocation of PKCα from the cytosol to the plasma membrane.  A small percentage of 
cells in each culture demonstrated spontaneous translocation of all 3 PKC isozymes 
examined in unstimulated cultures (2.99-7.69% N = 104-568).  Upon exposure to PMA 
for 10 minutes, all 3 isozymes translocated to the plasma membrane in a subset of cells 
(50.17% of 291 cells for PKCα, 20.34% of 188 cells for PKCβ, and 27.59% of 203 cells 
for PKCε), confirming that the protocol was sufficient to demonstrate translocation 
(Mynlieff, unpublished results).  For PKCβ and PKCε, the percentage of cells 
demonstrating translocation to the plasma membrane in the presence of 10 µM baclofen 
Figure 4.6: Activation of GABAB receptors causes translocation of PKCα in cultured hippocampal 
neurons. A) Prior to fixation for immunocytochemistry, cultured hippocampal neurons were treated 
with control media, the phorbol ester PMA (1 μM) in media, or baclofen (10μM) in media for 10 
minutes. Cultured neurons were labeled with anti-PKCα, anti-PKCβ, or anti-PKCε antibodies 
followed by Dylight® 488 conjugated secondary antibodies for visualization (green).  Nuclei are 
stained blue with DAPI B) The percent cells demonstrating translocation of PKCα, PKCβ, and 
PKCε in control cultures (black bars) was compared to the percent cells demonstrating translocation 
of PKCα, PKCβ, and PKCε following stimulation with the baclofen. N=568, 478, 104, 183, 183, 
and 177 for the PKCα control, PKCα with baclofen, PKCβ control, PKCβ with baclofen, PKCε 
control, and PKCε with baclofen. Scale bar: 20 μm.  *P <  0.0001. 
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was not significantly different than under nonstimulating conditions.  However, the 
percentage of cells demonstrating translocation of PKCα with baclofen treatment (9.83%, 
N = 478) was significantly higher than the percentage of cells demonstrating spontaneous 
translocation under nonstimulating conditions (2.99%, N = 568; Fisher’s exact test, P < 
0.0001, Mynlieff, unpublished results).  Therefore, since only PKCα was translocated to 
the membrane upon baclofen treatment and not PKCβ or PKCε, PKCα is most likely the 
isozyme activated in the signal transduction pathway.   
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DISCUSSION 
 
Data presented here suggest that, in contrast to the commonly described coupling 
of GABAB receptors to Gαi/o G proteins, GABAB receptors can also couple to Gαq G 
proteins.  This polygamous coupling leads to the activation of PKCα and, independent of 
CaMKII, results in enhanced L-type calcium current in neonatal rat hippocampal 
cultures.  The current hypothesis, shown in figure 4.7, is that once a ligand binds to the 
external face of the GABAB receptor, Gαq is released from the intracellular side of the 
receptor.  The α subunit activates the enzyme phospholipase Cβ, (PLCβ) which cleaves 
the membrane- bound phosphatidylinositol bisphosphate (PIP2) into diacylglycerol 
(DAG) and inositol tris-phosphate (IP3).  The conventional isozyme PKCα, which 
requires both DAG and calcium for its activation, may directly phosphorylate the L-type 
channel such that it passes more current when open.  However, this phosphorylation 
event may not be directly mediated by PKC; it is possible an unknown protein acts as an 
intermediary between PKCα and the L-type channel. 
 In order to test the involvement of Gαq in the signal transduction pathway, I 
employed a knockdown strategy which inhibits translation of target mRNA via 
morpholino (MO) oligonucleotides.  Traditionally, knockdown of protein expression 
involves the use of siRNA; however, MO offer a number of advantages.  siRNA are 
sensitive to intracellular enzymes, can trigger innate immune response, and can cause 
changes in the methylation state of DNA (Bayne and Allshire 2005; Judge et al., 2005; 
Kawasaki et al., 2005; Marques and Williams 2005).  None of these actions occur with 
MO, and they have been shown to be taken up in cultured cells, through endocytosis 
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stimulated by the Endo-Porter peptide (Hudziak et al., 1996).  The lack of enzymatic 
degradation makes MO particularly well suited for these studies because of the relatively 
long half-life of G proteins.  Despite these advantages, the use of MO in mammalian 
systems is still relatively new compared to use in other model organisms, particularly 
Danio rerio.  Indeed, there is only one report of Endo-Porter mediated MO knockdown in 
mammalian neurons (Chih et al., 2006).  Thus, validation of protein knockdown 
demonstrated here highlights the usefulness of this technique.   
 
  
 
 
 
 
 
 
 
 
Western blot analysis indicated that morpholinos were efficient in knocking down 
Gαq in primary hippocampal cultures, but given the high similarity in G protein mRNA 
Figure 4.7:  The current model for the pathway, which begins with GABAB receptor activation 
and results in enhanced L-type current.  Ligand binding to the GABAB receptor leads to the 
activation of a Gαq G protein, which putatively activates PLC.  The activity of PLC hydrolyses 
PIP2 into DAG and IP3, which can activate PKC, specifically the α isozyme.  PKCα bypasses 
CaMKII, leading to changes in the L-type calcium channel, such that L-type current is enhanced 
when the channel opens.  Whether PKCα directly interacts with the channel is unknown.  
Abbreviations: PLC phospholipase C, PIP2 phosphatidylinositol 4,5-bisphosphate, DAG 
diacylglycerol, IP3 inositol trisphosphate, PKC protein kinase C.   
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sequence to which MOs bind, it was necessary to verify specificity of this knockdown.  
The most likely candidate for nonspecific knockdown was Gα11, due to its high sequence 
homology with Gαq.  The first 25 coding amino acids (the site of MO binding) are 92% 
identical.  Despite MO being designed with 100% fidelity to the target, nonspecificity 
was a concern because of this sequence similarity. Furthermore, Gα11 may compensate 
for missing Gαq in Gαq-deficient mice, suggesting functional overlap as well (Korhonen 
et al., 2009).  Data shown here suggests significantly higher expression of Gαq than Gα11, 
consistent with other reports (Milligan 1993; Ihnatovych et al., 2002).  However, caution 
must be used in interpreting these results.  Because different antibodies were used to 
detect each protein, it is possible that the Gα11 antibody is less effective and simply gives 
a weaker signal than the Gαq antibody, even if there is abundant protein.  However, these 
Western blot data agree with other reports of greater Gαq expression.  Furthermore, Gαq 
expression is highest during the first postnatal week (Ihnatovych et al., 2002); this 
temporal peak in expression corresponds to the time when the highest percentage of 
neurons demonstrate L-type calcium current enhancement with baclofen (Bray and 
Mynlieff 2009).   
 Experimental data from both electrophysiological and calcium imaging 
experiments support the hypothesis that Gαq is the G protein that couples to the GABAB 
receptor, ultimately leading to enhanced L-type current.  In both paradigms, knockdown 
of Gαq eliminated the enhancing response.  These data were supported by confocal 
imaging, which demonstrated the colocalization of GABAB receptors and Gαq G proteins.  
However, Mannoury la Cour et al. used an antibody/scintillation proximity assay to 
demonstrate a lack of coupling between Gαq/11 and GABAB receptors (2008).  One 
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potential problem with this study is that the reported EC50 value for baclofen was 
approximately 50 µM for Gαi/o coupling.  This value is much higher than those used by 
others examining Gαi/o activation by GABAB receptors.  Furthermore, the enhancing 
effect of baclofen on calcium current was seen at high nanomolar concentrations, while 
attenuation of calcium current requires micromolar concentrations (Shen and Slaughter 
1999).  Thus, it is possible that the assay used by Mannoury la Cour et al. (2008) is not 
sensitive enough to show Gαq/GABAB coupling at low agonist concentrations.   
 The functional GABAB receptor is a heterodimer consisting of two subunits, 
GABAB1a and GABAB1b, of which GABAB1b interacts with the G protein.  The molecular 
interaction between the GABAB receptor and Gαi/o involves both the second and third 
intracellular loops of GABAB1b (Havlickova et al., 2002; Duthey et al., 2002).  This 
interaction occurs with the extreme C-terminus of the G protein (Franek et al., 1999).  
The lack of sequence homology between Gαi/o and Gαq suggests that Gαq must couple to 
sites unique to those examined previously.  Although this is the first example of GABAB 
receptors coupling to Gαq, coupling of a receptor to multiple G proteins has been shown 
previously, including receptors that couple to both Gαq and Gαi/o.  Another possibility is 
that the βγ subunit of the Gαi/o G protein may increase intracellular calcium by the same 
pathway as Gαq.  This has been shown to occur in airway smooth muscle (Mizuta et al., 
2011).  In this study, stimulation of GABAB receptors activated Gαi G protein and an 
increase in calcium entry was observed.  When βγ subunit signaling was 
pharmacologically blocked, no calcium entry was observed and IP3 production was 
reduced.   Furthermore, direct stimulation of PLCβ by βγ has been reported in COS-1 
cells (Camps et al., 1992), and this stimulation may occur synergistically with stimulation 
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by Gαq from a separately activated receptor (Smrcka and Sternweis 1993).  However, if 
current enhancement was mediated by Gαi/o βγ subunits, it would be sensitive to pertussis 
toxin.  When PTX was applied to cell cultures, baclofen-mediated current enhancement 
persisted.  Furthermore, since βγ signaling requires functional α subunit interaction for 
proper assembly (Smrcka 2008), knockout of Gαq would likely prevent βγ from initiating 
cascades as well.   
 One question that remains unanswered is why only a subset of neurons show L-
type enhancement when GABAB receptors are stimulated.  The answer is likely that, with 
16 different types of interneurons found in the hippocampus, perhaps only (a) certain 
type(s) exhibit this response. Immunohistochemical data have provided clues to a more 
specific, functional answer.   Neurons (presumably interneurons) in both the stratum 
oriens and the stratum radiatum showed colocalization of GABAB receptors and Gαq G 
proteins.  Studies are underway to determine which type(s) of interneuron(s) is 
responsible for the current enhancement observed.  By examining colocalization of Gαq 
and interneuronal markers already known to colocalize with GABAB receptors, the 
specific cell type that demonstrates current enhancement can be identified.  For example, 
cholecystokinin (CCK), somatostatin, calbindin, and neuropeptide Y all demonstrated 
colocalization with GABAB receptors.  These markers help define cell type.  The 
hypothesis is that at least one of these markers will colocalize with Gαq, which would 
indicate the type of cell which exhibits L-type enhancement.  Elucidating the cell type 
would provide a basis for determining the physiological relevance for GABAB mediated 
enhancement of L-type current.    
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CHAPTER 5 
Calcium/calmodulin-dependent kinase II inhibitor CK59 demonstrates nonspecific, 
reversible inhibition of voltage-gated calcium channels 
INTRODUCTION  
Calcium-calmodulin dependent kinase II (CaMKII) is a crucial signaling 
molecule involved in many of the most fundamental behaviors of neurons, such as gene 
expression and synaptic plasticity due to long term potentiation.  It follows that the 
distribution of this protein is widespread throughout the nervous system, and makes up 
between 1-2% of total proteins in neurons.  Given both its importance and its abundance, 
CaMKII-mediated processes are currently under intense investigation.  One of the most 
common ways to study the role of CaMKII is via pharmacological inhibition.  Changes in 
the neuron may be revealed when a specific CaMKII inhibitor is applied, allowing the 
investigator to attribute these changes to CaMKII activity.  Unfortunately, a common 
problem with kinase inhibitors, including CaMKII inhibitors, is their lack of specificity; 
they may inhibit more targets than just CaMKII.  Therefore, new, more specific inhibitors 
are in high demand.  This demand extends to a clinical setting, where more specific 
CaMKII-related drugs would help avoid potentially harmful side effects. 
 Over 30 different isoforms (made up of various alternatively spliced α, β, γ, and δ 
subunits) of CaMKII have been reported (for review see Fink and Meyer 2002; Wayman 
et al., 2011).  The primary neuronal subunits are α and β, which are highly homologous.  
Subunits come together either as homo- or heterododecihedromers, with each subunit 
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containing a catalytic, regulatory, and oligomerization domain.  The structure of CaMKII 
is analogous to a flower petal, where the oligomerization domain makes up the inner 
core, while that catalytic and regulatory domains form a stack of 2 hexomers (Gaertner et 
al., 2004; Rosenberg et al., 2006; see figure 1.8 from introduction).  When calmodulin 
(CaM) binds to the regulatory domain, autoinhibition is disrupted, and the particular 
subunit interacting with CaM is free to autophosphorylate neighboring subunits, which 
causes their catalytic subunits to become active.  CamKII inhibitors reduce the activity of 
the enzyme in different ways.  For example, one of the most commonly used inhibitors, 
KN93, works to compete with CaM binding to the regulatory domain.  This is in contrast 
to an inhibitor such as autocamtide 2-related inhibitory peptide (AIP), which specifically 
inhibits autophosphorylation (Ishida et al., 1995; Song et al., 2010).  It follows that with 
different forms of inhibition, there are many different off target effects.   
 CaMKII phosphorylates a wide variety of proteins to modulate their activity, 
including voltage-gated calcium channels.  Regulation of these channels, either positive 
or negative, occurs at sites on the channel within the intracellular loops or at the N and C 
termini.  G protein βγ subunits (Li et al., 2004) as well as multiple kinases (Park et al., 
2006; Wang et al., 2009) have been shown to interact with all types of voltage-gated 
calcium channels.  Since changes in intracellular calcium concentration often work as a 
switch for many physiological processes, there is a great deal of interest surrounding how 
the behavior of these channels can be modified by various signaling molecules.  The most 
direct approach is to expose cultured neurons to cell-permeable CaMKII inhibitors and 
observe what, if any, effect CaMKII inhibition has on L-type current enhancement.   
However, kinase inhibitors have been complicated by nonspecificity and off target 
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effects.  For example, CaMKII inhibitor KN93 interacts with L-type calcium channels by 
reversibly inhibiting them (Gao et al., 2006).  Previously regarded as one of the cleanest, 
most potent CaMKII inhibitors in existence, KN93 is not well suited to be used in my 
studies, which examine calcium channel activity.  Recently a compound known as CK59 
was synthesized, and has been shown to inhibit CaMKII activity (Konstantopoulos et al., 
2007).  While originally created to investigate the kinase responsible for insulin-mediated 
GLUT 4 glucose transporter translocation, CK59 also offered an attractive option to those 
studying CaMKII and calcium channels, due to its potency (IC50 < 10 μM) and cell 
permeability.  I selected this inhibitor because of these factors, but it was immediately 
clear that similarly to KN93, CK59 displayed nonspecific inhibition in a reversible 
manner.  Thus, I sought to better describe this nonspecific inhibition by examining which 
type of calcium channel (N-, P/Q- or L-type) was affected, as well as the potency of the 
inhibition.   
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RESULTS 
CK59 inhibits depolarization-induced calcium entry 
 Ratiometric calcium imaging was used to explore the effects of CK59 and cell-
permeable autocamtide-2 related inhibitory peptide (Ant-AIP-II).  Ant-AIP-II is a 
compound that is an analogue of autocamtide-2 related inhibitory peptide (AIP) in which 
Ala3 and Val10 are replaced with Lys and Phe respectively, giving the Ant-AIP-II 10 
times greater potency than AIP (IC50  for Ant-AIP-II 4 nM, versus 40 nM for AIP).  
Furthermore, Ant-AIP-II contains the Antennapedia transport sequence fused to its amino 
terminus to enhance cell permeability.  Ant-AIP-II has been demonstrated to successfully 
enter both glia and neurons (Watterson et al., 2001; Mauceri et al., 2004).  Cells were 
depolarized with high KCl for 30 seconds, then KCl was washed away and cells allowed 
to return to baseline.  Subsequently cells were pretreated with Ant-AIP-II for 15 seconds, 
followed by coapplication of Ant-AIP-II and high KCl for 30 seconds.  This solution was 
washed away, and a final high KCl stimulation was performed.  When 50 μM was CK59 
applied (IC50 = 10 μM), the high KCl solution was not able to elicit as large an increase 
in intracellular calcium (Figure 5.1a).  However, Ant-AIP-II treatment (50 nM) shows no 
significant effect of on calcium entry through voltage-gated channels using the same 
experimental protocol (Figure 5.1b).  This CK59-mediated effect was reversible, as the 
response to the high KCl depolarization after washout was restored to baseline levels.  On 
average, the increase in intracellular calcium was 44.83 ± 1.88% when compared to 
control levels of intracellular calcium (the increase seen when high KCl alone was 
perfused onto the cells (Figure 5.1c, N = 128; paired t-test, P < 0.001). There was no  
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significant reduction in calcium entry when neurons were exposed to Ant-AIP-II (94.68 ± 
CaMKII 1.29) compared to control levels. (N = 255).  Neither inhibitor had any effect on 
the baseline levels of intracellular calcium.  These data suggest that the novel 
inhibitor CK59 shows off-target inhibition of voltage-gated calcium channels.  However, 
the data do not exclude the possibility that CK59 enhances the rate of calcium extrusion 
in the presence of high intracellular calcium, thereby decreasing intracellular calcium 
levels measured. 
 
Figure 5.1: CaMKII inhibitor CK59 but not 
Ant-AIP-II signiﬁcantly attenuates the amount 
of high KCl-induced increase in intracellular 
calcium when measured with ratiometric 
imaging. A: Example of 340/380 ratio 
obtained with high KCl solution alone or high 
KCl solution in the presence of 50 µM CK59. 
Each line shown represents an individual cell 
(N = 6). B: The same conditions as in A, but 
using 50 nM Ant-AIP-II (N = 6). C: Average 
change in intracellular calcium as determined 
by the 340/380 ratios with KCl alone (solid 
bars), KCl with CK59 (crossed hash bar, N = 
128), or KCl with Ant-AIP-II (diagonal 
hashed bar, N = 255, *Paired t test, P < 0.001) 
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CK59 decreased calcium influx in a concentration dependent manner 
 In order to get a measurement of the potency of the CK59-mediated inhibition of 
voltage-gated calcium channels, a concentration-response curve was constructed.  High 
KCl-induced increases in intracellular calcium were measured in the presence of 500 nM 
– 250 μM CK59.  The solubility in DMSO limited the highest concentration of CK59.  
Control experiments done with DMSO diluted 1:250 in Ringer’s solution with no CK59 
did not affect high KCl-induced calcium influx at this concentration (data not shown).  
These concentration-response curve data were fit with a 3 parameter sigmoidal curve, 
which assumed that if the concentration was increased to high enough levels, all calcium 
entry would be blocked.  The curve generated an IC50 of 52 μM (Figure 5.2).  It is 
possible that this is an overestimate; if all calcium entry is not completely inhibited and 
instead CK59-mediated inhibition at a concentration of 250 μM is the actual maximum, 
then the IC50 would be closer to 22 μM.   
 
  
 
 
 
 
 
 
Figure 5.2: Various concentrations (0.5, 
5, 20, 50, 250 µM; N = 122, 51, 166, 326, 
122, respectively) of CK59 were applied 
to cells during high KCl-induced 
depolarization.  The percent inhibition of 
high KCl-induced intracellular calcium by 
CK59 was calculated as 100% −
(100 𝑥
(𝐹𝑢𝑟𝑎 𝑅𝑎𝑡𝑖𝑜 𝑖𝑛 𝐶𝐾59+𝐾𝐶𝑙)
(𝐹𝑢𝑟𝑎 𝑅𝑎𝑡𝑖𝑜 𝑖𝑛 𝐾𝐶𝑙) ).  Data 
were fit with a 3 parameter sigmoidal 
curve (r2 = 0.983), to determine an IC50 
value of CK59 in decreasing calcium 
influx, 52 µM.   
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The effects of CK59 on voltage-gated calcium current were measured directly 
using whole-cell patch clamp electrophysiology.  Currents were elicited by a 300 ms 
depolarizing pulse to +10 mV from a holding potential of -80 mV.  CK59 was applied via 
U-tube perfusion (Figure 5.3a).  Calcium currents often show run-up or run-down of 
current, so control currents before and after CK59 treatment were used to construct a 
linear regression line surrounded by a 95% confidence interval (Figure 5.3b).  If the 
inhibitor had no effect, the current elicited when CK59 was present would fall within the 
confidence interval.  However, the total current was reduced with CK59 application, in 
agreement with calcium imaging data.  In all 15 cells tested, CK59 significantly reduced 
the current an average of 32.05 ± 1.86% when compared to the linear regression line 
(Figure 5.3a).  The difference in reduction of calcium entry observed when using 
ratiometric calcium imaging versus whole cell patch clamp electrophysiology likely 
stems from the length of time neurons were stimulated.  In calcium imaging experiments, 
neurons were depolarized for 30 seconds so that the majority of calcium influx is through 
long lasting L-type channels, whereas electrophysiological experiments depolarize 
neurons for a relatively short 300 ms.    
 
CK59 decreases calcium entry through more than one voltage-gated calcium 
channel 
Since it had previously been reported that the CaMKII inhibitor KN93 reduced L-
type calcium current, I assessed whether specifically L-type calcium channels were 
similarly inhibited by CK59 with whole cell recording. Calcium currents were measured 
during the final 50 ms of a 300 ms depolarizing pulse to +10 mV to minimize the 
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contribution of other current components while maximizing the long lasting (L-type) 
component of the current. Notably, N-, P/Q-, and R-type currents are still present during  
this period, as demonstrated in figure 5.3c, where current still remains after the L-type 
calcium channel antagonist nimodipine (20 μM) was used. Thus, the current remaining in 
the presence of nimodipine should primarily be comprised of N-, P/Q-, and R-types of 
calcium current. If CK59 only inhibited L-type channels, then the addition of CK59 in the 
presence of nimodipine should not further inhibit the total calcium current because the 
channels would already be blocked. Figure 5.3c illustrates the calcium current elicited in 
the presence and absence of CK59 (50 μM) in a cell pretreated with nimodipine (20μM). 
The current was reduced with CK59 in a reversible manner similarly to the non-
nimodipine treated cells. CK59 caused a significant decrease in calcium current with an 
average reduction of 27.54 ± 4.66% (N = 7, Figure 5.3c). The reduction in voltage-gated 
calcium current elicited in the presence of the L-type calcium channel antagonist suggests 
that CK59 may inhibit N-, P/Q-, and/or R-type current(s). 
Ratiometric calcium imaging experiments were done to confirm that CK59 can 
reduce calcium entry in the presence of an L-type calcium channel antagonist. 
Nimodipine (20 μM) was present in the bath for the entire time course of the experiment 
to block L-type calcium channels, and high KCl solution alone or high KCl solution with 
CK59 (50 μM) were applied acutely (Figure 5.4). Application of CK59 under these 
conditions reduced calcium entry to 43.73 ± 1.38% (N = 185) of the average calcium 
entry elicited by high KCl application alone. Given that both calcium current and entry 
decreased in the presence of the L-type calcium channel blocker nimodipine, it was 
hypothesized that CK59 exerts its effects by inhibiting another calcium channel type than 
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Figure 5.3: Calcium currents elicited by a 300 ms depolarizing pulse +10 mV from a holding 
potential of -80 mV demonstrate the nonspecific effects of CK59 (50 μM) on voltage-gated 
calcium channel types.  A: CK59 application reduces whole cell calcium current in normal 
recording solution. Currents were recorded before (black trace), during (grey trace) or after 
(light grey trace) application of CK59.  B: Control calcium currents were measured before and 
after application of CK59 (filled circles) and fit with a linear regression line surrounded by a 
95% confidence interval (dashed line).  Calcium currents elicited in the presence of CK59 (grey 
diamonds) fell outside the confidence interval for the control currents.  The percentage of 
current blocked by CK59 was calculated by comparing the current in the presence of CK59 to 
the regression line for that specific timepoint. C: 20 μM nimodipine was bath applied and 
voltage-gated calcium currents were recorded before (black trace) during (grey trace) and after 
(light grey trace) application of CK59 (50 μM).  D: 2 μM ω-conotoxin MVIIC was bath applied 
and voltage-gated calcium currents were recorded before (black trace) during (grey trace) and 
after (light grey trace) application of CK59 (50 μM).  The traces illustrated in A, C, and D were 
recorded in different neurons.  E: Average decrease in voltage-gated calcium currents seen with 
CK59 application (50 μM) in control bathing solution (N = 15), with 20 μM nimodipine (N = 
7), and with 2 μM ω-conotoxin MVIIC (N = 5) in the bath. *Unpaired t test, P < 001. 
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L-type calcium channels, suggesting a different nonspecific effect from that of CaMKII 
inhibitor KN93.  However, the effect of CK59 on L-type calcium channels may have 
been masked because nimodipine would already be blocking L-type channels in these 
experiments. Therefore, experiments were performed to address the effect of CK59 more 
specifically on L-type channels. 
To clarify if L-type calcium channels could also be blocked by CK59, ω-
conotoxin MVIIC (2 μM) was added to the bath during electrophysiological studies to 
block N- and P/Q-type calcium channels. The current in figure 5.3d is drastically reduced 
due to the presence of MVIIC. Comparing the raw current in 5.3c with the L-type 
channel blocker nimodipine with the raw current in 5.3d with ω-conotoxin MVIIC 
suggests that while L-type current is certainly present in these neurons, currents sensitive 
to ω-conotoxin MVIIC (N- and P/Q-type) make up the bulk of the high voltage activated 
whole-cell current in neonatal neurons of the superior hippocampus when a 300 ms 
depolarizing pulse is applied. Addition of CK59 (50 μM) reduced the current even  
 
 
 
 
 
Figure 5.4: CaMKII inhibitor CK59 attenuates the high KCl-induced increase in intracellular 
calcium in the presence of L-type calcium channel blocker nimodipine, when measured using 
calcium imaging.  Nimodipine (20 μM) was perfused during the entire measurement period.  
The 340/380 ratio was measured in response to high KCl solution before and during CK59 
application (50 μM), and representative cells are shown (N = 7 shown, total N = 185).  Each 
line represents an individual cell.   
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further, so that very little current remained when MVIIC and CK59 were simultaneously 
applied. Calcium currents in these studies were decreased an average of 67.47 ± 10.38% 
(N = 5; Figure 5.3d) which was a significantly larger decrease by CK59 than that seen 
when ω-conotoxin MVIIC was not present (unpaired t-test, P < 0.001, Figure 5.3e). 
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DISCUSSION 
 
 Data presented here show the off-target action of the CaMKII inhibitor CK59 on 
voltage-gated calcium channels.  Both electrically stimulated currents in whole cell 
electrophysiological recording and high KCl-induced calcium influx were significantly 
reduced by CK59 in a dose-dependent manner.  However, determining the exact calcium 
channel(s) targeted by CK59 is more difficult.  Studies done in the presence of ω-
conotoxin MVIIC strongly argue for L-type channel inhibition.  As expected, when 
MVIIC was applied to the bath, the remaining current was reduced.  When CK59 was 
applied while MVIIC was in the bath, there was near complete extinction of current in the 
majority of cells tested.  However, in the presence of L-type channel blocker nimodipine, 
both calcium current and calcium entry were reduced when CK59 was applied.  These 
data seem to contradict experiments performed in MVIIC.  However, one possibility is 
that when nimodipine is present, L-type current is already being blocked.  Therefore, any 
effect on L-type channels would be masked.  The decrease in calcium levels in the 
presence of nimodipine after CK59 application does suggest inhibition of additional 
channels besides the L-type calcium channel.  One possibility is that R-type calcium 
channels are inhibited by CK59.  However, R-type current in the entorhinal cortex makes 
up only 11-13% of total calcium current (Castelli and Magistretti 2006).  The small 
amount of current seen in the cells treated with MVIIC also suggests a large component 
of calcium influx is through N- and P/Q-type channels.  Even if complete blockade of R-
type current was assumed, this would likely not make up for the amount of inhibition 
seen in nimodipine-treated cells.  There was a 27.54% reduction in whole cell calcium 
95 
 
current and 56.27% reduction in high KCl-mediated calcium entry when nimodipine was 
present.  These data suggest that even if R-type channels are affected along with L-type 
channels, there must be another channel that is inhibited by CK59. 
 A second possibility that is that L-type channels were not completely blocked.  
This seems unlikely due to the high concentration of nimodipine used in these studies 
(IC50 = 139 nM for Cav 1.2 and 3 µM for Cav 1.3, respectively; Catterall 2005).  It is 
more likely that at least one of the channels blocked by MVIIC is susceptible to 
inhibition by CK59.  In either case, it seems that CK59 inhibits L-type channels as well 
as others.  While the identity of the other channels that CK59 may inhibit in addition to 
L-type channels is not completely clear, it is evident that CK59 has off-target effects that 
inhibit the entry of calcium through voltage-gated calcium channels.   
 Figure 5.3d shows the effect of blocking N- and P/Q-type currents 
pharmacologically with MVIIC, then applying 50 μM CK59.  The result of this 
experiment is that the remaining current not blocked by MVIIC is nearly completely 
blocked with CK59, and this current would likely be L-type current.  Figure 5.3c shows 
the effect of blocking L-type current with nimodipine, then applying 50 μM CK59.  
While CK59 reduces current, there is a large component that still remains.  There are two 
possibilities for this effect.  First, it is possible that L-type channels have a lower IC50 for 
CK59 than the measured 52 μM for all calcium channels collectively.  Thus, a complete 
block of L-type channels may occur at 50 μM.  The same concentration may not 
completely block N- and P/Q-current.  Alternatively, it is possible that there is a 
component of the current which CK59 does not inhibit whatsoever.   For example, if in 
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Figure 5.3c, L-current was blocked by nimodipine and only P/Q-current was blocked by 
CK59, the remaining current could be N-type current, unaffected by either inhibitor.    
CK59’s IC50 for inhibition of CaMKII activity is <10 μM.  Other nonspecific 
CaMKII inhibitors that inhibit L-type calcium channels are more potent, both in their 
primary and off-target effects.  For example, the IC50 for KN93’s effect on CaMKII is 
0.37 μM (Sumi et al., 1991), whereas its IC50 for L-type channel inhibition is 
approximately 1μM (Gao et al, 1996).  The IC50 of the structurally related inhibitor KN62 
is 0.9 μM for CaMKII activity; the IC50 for its off-target effects on calcium entry is 
approximately 0.5 μM (Sihra and Pearson 1995).  Given the relatively close IC50 values 
for primary and off-target effects of these CaMKII inhibitors, caution must be exercised 
when selecting a compound to pharmacologically inhibit CaMKII activity.    
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CHAPTER 6 
GENERAL DISCUSSION 
The central findings of work presented here detailed the signal transduction 
pathway of L-type calcium current enhancement upon GABAB receptor stimulation.  It 
was demonstrated that GABAB receptors are capable of coupling to Gαq G proteins; this 
activation leads to increased PKCα activity.  As reported previously in our laboratory and 
in others, this increased PKCα signal is necessary to increase L-type calcium channel 
activity.  The entire cascade circumvents CaMKII.  However, it is not clear whether 
PKCα phosphorylates L-type channels directly, or if there are more intermediaries in the 
process of calcium current enhancement.   
 
Determination of the L-type channel isoform 
The neuronal L-type calcium channel has two isoforms, Cav 1.2 and Cav 1.3.  
Because both channels are sensitive to dihydropyridines, there is no current way to 
separate their functions pharmacologically.  Furthermore, while conditional knockout 
animals have been generated, there is the possibility that one isoform will be upregulated 
to compensate for the loss of the other isoform.  Thus, it has been difficult to ascribe 
specific functions to a specific isoform.  One question that remains in the signal 
transduction pathway described here is which calcium channel isoform mediates current 
enhancement.  Expression data from the Mynlieff laboratory showed that expression of 
Cav 1.2 peaks within the first week of development, then decreases rapidly.  These data 
have been confirmed by other investigators (Morton et al., 2013).  Peak expression of Cav 
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1.2 coincides with the time point where the greatest number of cells show enhanced 
calcium entry after GABAB receptor activation, suggesting that Cav 1.2 is the channel 
responsible for mediating this enhancement.  However, Cav 1.3 is expressed at P7 as well, 
albeit at lower levels.  Furthermore, co-immuprecipitation and yeast two-hybrid assays 
show a physical interaction between the GABAB receptor and Cav 1.3 (Park and Rhim 
2010).  These data suggest Cav 1.3 may be responsible for current enhancement.  A final 
possibility is that current enhancement occurs in both Cav 1.2 and Cav 1.3.   Baclofen has 
been shown to enhance calcium levels through both Cav 1.2 and Cav 1.3 when measured 
in transfected HEK293 cells (Im and Rhim 2012).   Thus, there is not a clear consensus 
on the calcium channel isoform that mediates L-type current enhancement in cultured 
hippocampal neurons. 
 Experiments using morpholino (MO) oligonucleotides to knock down either Cav 
1.2 or Cav 1.3 will help identify the isoform mediated current enhancement.  Knockdown 
of Cav 1.2 would allow the effects of Cav 1.3 exclusively to be observed.  For example, if 
knockdown of Cav 1.2 abolishes L-type enhancement, then this is the channel targeted by 
GABAB receptor activation.  If enhancement persists, then Cav 1.3 must be at least 
partially responsible for L-type enhancement.  These studies should be feasible because 
use of MO in protein knockdown have been successful in our rat cultures.  However, 
should MO knockdown prove unsuccessful, there is the possibility of determining which 
channel mediates L-type enhancement by examining the phosphorylation state of the 
channel.  One drawback to this strategy is that it assumes enhancement is due to a 
phosphorylation event.  A second drawback is this strategy would require purification of 
proteins that are not highly expressed (particularly Cav 1.3).  However, identification of 
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the channel remains a crucial step in elucidating the physiological relevance of L-type 
enhancement.  
 
The possibility of BDNF-mediated KCC2 expression 
The influx of current through L-type calcium channels is critical throughout 
development and into adulthood.  During embryogenesis, L-type current is required for 
neural crest cell migration and differentiation (Moran 1991).  It is known that the 
hippocampus is a crucial site for long-term potentiation (LTP), which underlies synaptic 
plasticity.  Pharmacological inhibition of L-type channels results in impaired induction of 
specific forms of LTP in young (P21 - P28) rats (Kapur et al., 1998).  Particularly 
pertinent to studies in the Mynlieff laboratory is the relationship between the 
neurotransmitter GABA and L-type current as the hippocampal circuitry matures. During 
embryonic development, GABA acts as an excitatory neurotransmitter, but undergoes a 
switch to mediate inhibition (for review see Blaesse et al., 2009).  Depending on 
experimental conditions (region of the hippocampus examined, cultured or slice 
preparation, recording parameters, etc.), the switch in the effect of GABA on 
hippocampal neurons ranges from P5 to P13 (Tyzio et al., 2007).  This switch is based on 
chloride gradients established by chloride transporters, and the transporters themselves 
are regulated by calcium influx through L-type channels.  Maturation of GABAergic 
circuitry is dependent on GABA itself (Ganguly et al., 2001).  Activation of GABAA 
receptors is sufficient to open voltage-gated channels, and it is particularly the calcium 
flowing through L-type channels which regulate chloride transporter expression levels 
(Bray and Mynlieff 2009).  Indeed, treating cultured cells with L-type channel 
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antagonists reduces expression of the chloride transporter K+Cl-co-transporter 2 (KCC2, 
Bray and Mynlieff 2009), the chloride transporter that is responsible for chloride efflux 
during adulthood.  
Currently, the precise mechanism for how changes in L-type calcium current 
changes the expression of KCC2 is unknown.  One hypothesis is that brain derived 
neurotrophic factor (BDNF) expression upregulates the levels of KCC2 in an L-type 
calcium-dependent manner.  Several lines of evidence support this hypothesis.  First, 
BDNF levels are higher in the first two weeks of postnatal development (Sathanoori et 
al., 2004), coinciding with the switch in GABAergic signaling from excitatory to 
inhibitory.  Secondly, GABAA-induced increases in intracellular calcium stimulate 
BDNF expression.  The BDNF gene is complex; it encodes 4 exons that are noncoding on 
their own, as well as 4 promoters (Figure 6.1, Timmusk et al., 1993).  Alternative splicing 
produces a single exon which encodes the BDNF protein.  Within the four exons, 
transcripts that contain exon III are most sensitive to calcium-mediated induction.  Within 
exon III, the transcription factor CREB is required to induce expression, but it is not 
sufficient.  The promoter of exon III contains a binding site for 3 distinct transcription 
factors, including the most distal binding site, calcium response element (CaRE1, Tao et 
al., 2002).  Induction of the BDNF gene can occur when CaRE1 is bound to the 
transcription factor CaRF.  The activity of CaRF is dependent both on neuronal type and 
calcium concentration.  CaRE1 does respond to depolarization when isolated from the 
BDNF promoter, but exhibits cooperativity with other CaREs.  Currently, there are 3 
known CaREs, and transcription factors are required at each CaRE in order to express 
exon III-containing BDNF.  It is thought that different combinations of calcium-
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dependent transcription factors may be a mechanism for cell type specificity of gene 
induction due to depolarization.   
Furthermore, the methylation state of BDNF is also influenced by intracellular 
calcium.  Methylation of DNA commonly occurs where cytosine nucleotides reside next 
to guanine nucleotides (CpGs).  Methlyated CpGs bind several proteins, including 
methyl-CpG binding protein 2 (MeCP2).  MeCP2 binds to the promoter III region of 
BDNF DNA and functions to repress expression (Zhou et al., 2006).  However, an 
Figure 6.1: BDNF gene regions, and regulation of exon III.  A: The BDNF gene can generate 8 
distinct protein transcripts.  There are 4 possible initial exons which can be alternatively spliced 
to form a single 3’ exon.  Each of the 4 splice variants may use one of two polyadenylation sites 
within the 3’ untranslated region.  B: The promoter III region on the BDNF gene is activated in 
response to calcium influx.  At least 3 transcriptional activators, CaRF (calcium response factor), 
USF (upstream stimulatory factor) and CREB (calcium response element-binding protein) must 
be recruited to the promoter.  In addition, MeCP2 (methyl CpG binding protein 2) must also be 
removed, which allows histone H3 to be acetylated (AC) and transcription of the BDNF gene to 
occur.  Phosphorylation of MeCP2 and CaRF occurs through calcium/calmodulin-dependent 
kinases that are activated by calcium entering, in part, through L-type channels (Adapted with 
permission from West et al., 98(20): 11024-11031 (2001). Copyright (2001) National Academy 
of Sciences, U.S.A. 
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activity-dependent increase in calcium triggers phosphorylation of MeCP2 in a CaMKII-
dependent mechanism (Chen et al., 2003).  Phosphorylation of MeCP2 releases it from 
the promoter and allows promoter III-dependent BDNF transcription.  Thus, increased 
intracellular calcium, potentially due to chloride efflux during development, can increase 
BDNF activity by two distinct mechanisms. 
The mechanism by which BDNF increases KCC2 expression is also complex.  
Early growth response 4 (Egr4) is a transcription factor whose expression increases 
during and after neuronal activity.  The KCC2 gene contains a binding site for Egr4 on its 
promoter (Uvarov et al., 2006).  BDNF application activates TrkB receptors which lead 
to increased ERK1/2 activity.  ERK1/2 in turn causes increased expression of Egr4, which 
is a requirement for transcription of KCC2 (Ludwig et al., 2011).  Importantly, a direct 
pathway between L-type calcium current and increased KCC2 has not been 
demonstrated, nor has the GABAB mediated enhancement of L-type current been 
implicated in changing expression of KCC2.  However, it has been shown that GABAB 
receptor activation increases L-type current, which results in increased levels of 
phosphorylated ERK1/2 (Im and Rhim 2012).  Furthermore, it has also been shown that 
activation of GABAB receptors increase secretion of BDNF (Kuczewski et al., 2011).  
Currently, there is not an established function for enhancement of L-type current in 
response to GABAB receptor activation.  However, experiments examining whether this 
increased calcium changes KCC2 expression could provide a functional association that 
is currently lacking.  
Besides causing increased synthesis of BDNF, L-type calcium current is also 
known to promote BDNF release.  Spontaneous α-Amino-3-hydroxy-5-methyl-4- 
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Figure 6.2: Influx of calcium current 
through L-type channels can induce 
BDNF release.  The 3 step model proposes 
that spontaneous AMPA receptor current 
activates L-type channels (step 1).  This 
increased intracellular concentration 
stimulates release of BDNF, which binds 
to pericellular TrkB receptors (step 2).  
Step 3 involves the activation of these 
receptors leading to long-term 
potentiation that is dependent on 
GABAergic signaling.  Figure reproduced 
with permission from John Wiley & Sons 
Publishing, Inc.  Kuczewski et al., 1;586 
(Pt 21): 5119-5128, (2008).  
isoxazolepropionic acid (AMPA) receptor activity in CA3 induces long term potentiation 
of GABAergic synaptic transmission; this potentiation is dependent on BDNF release, 
which in turn is dependent on L-type calcium current (Figure 6.2, Kuczewski et al., 
2008).  Spontaneous post-synaptic currents generated by AMPA receptor activity activate 
L-type channels.  Activation leads to a BDNF release event, where BDNF diffuses to 
neighboring TrkB receptors.  When these TrkB receptors are activated, a GABAA 
receptor-mediated induction of long term potentiation is observed.  Exactly how TrkB 
receptor activation leads to an increase in postsynaptic calcium is unknown.  However, 
these data demonstrate that, in addition to regulating production of BDNF, L-type 
calcium current may also be involved in activity-dependent release.  Importantly, this 
study showed that sustained glutamatergic activity is required for L-type channel 
activation.  Sustained glutamatergic receptor activation has been shown to downregulate 
GABAB receptors through increased lysosomal degradation (Maier et al, 2010).  One 
hypothesis for this effect is that enhancement of L-current, perhaps through GABAB 
receptor activation, is necessary to get a spike in BDNF production and release when  
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KCC2 is expressed during development.  Once GABAergic circuitry has matured,  
sustained glutamatergic activity supports basal BDNF levels and also downregulates 
GABAB receptor-mediated L-type enhancement.   
 
Identification of the interneuron class that displays L-type enhancement 
While the pathway between GABAB receptor activation and L-type current 
enhancement is now clearer, there is still a lack of understanding as to what cells are 
displaying this phenomenon.  Within the CA1 region of the hippocampus, there are 
separate populations of excitatory pyramidal cells and inhibitory GABAergic 
interneurons.  Generally, the pyramidal cells are considered a single population; because 
pyramidal cells make up a comparatively larger percentage of hippocampal cells than 
interneurons, it is unlikely that L-type enhancement is mediated through these cells.  
Conversely, there are at least 16 distinct classes of interneurons, with 12 classes that 
innervate particular regions of pyramidal cells and 4 classes that innervate other 
interneurons.  Immunocytochemical markers, electrophysiological recording, and 
morphological differences define the different classes; this classification has started to 
uncover their specific functional significance.  For example, one group of interneurons, 
known as basket cells, provide GABAergic synapses onto the soma and proximal 
dendrites of pyramidal cells (Somogyi and Klausberger 2005).  Their output is localized 
to control both timing and frequency of action potential generation in pyramidal cells.  
Control of spike timing is required for rhythmical synchronization of pyramidal cell 
networks, so basket cell output is essential in the generation of oscillatory firing.  
However, although basket cells may be morphologically similar and have similar targets 
105 
 
on pyramidal cells, there are distinct populations of basket cells that form 3 of the 16 
classes of interneurons.   
One of the 16 classes of inhibitory interneurons are basket cells that express 
parvalbumin (PV) but not cholecystokinin.  These PV+ basket cells show high frequency 
action potential firing (150 Hz) in short duration trains (Doischer et al., 2008).  Their 
action potentials are locked in phase to fast oscillatory network firing, and thus provide 
stable and consistent inhibitory output onto their targets.  These basket cells function 
differently than another class of interneurons, basket cells that express cholecystokinin 
(CCK).  CCK+ cells fire at more moderate frequencies (50 Hz), and their action 
potentials are not timed to fast oscillations like PV+ basket cells (Lee et al., 2011).  This 
less dependable firing leads to asynchronous release events seen only in CCK+ but not 
PV+ basket cells.  Given the differences in firing frequency and precise timed firing, 
these separate populations of basket cells likely make distinct contributions to the 
complete neural network.    
Finally, there is a third class of inhibitory interneuron that shows characteristics of 
a basket cell.  It is CCK+, but also exhibits immunoreactivity for vesicular glutamate 
transporter 3 (VGLUT3, Somogyi et al., 2004).  Because a cell that expresses a vesicular 
transporter is likely functionally distinct, it is put into a separate class.  However, so little 
information is known about this cell type that it is possible that CCK+/VGLUT3+ cells 
are actually the same CCK+ cells, but may express VGLUT3 at a particular time point.  
Despite advances in methods combining imaging and physiology, how interneuronal 
classes are divided is still highly debated. 
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Which of the 16 inhibitory interneuron types may demonstrate L-type 
enhancement? One hint comes from a study that examined colocalization between 
GABAB receptors and neurochemical markers in the hippocampal CA1 region (Sloviter 
et al., 1999).  PV+ interneurons do not demonstrate colocalization with GABAB 
receptors, which likely rules out any class that expresses parvalbumin, including PV+ 
basket cells.  However, GABAB receptors do colocalize with interneurons expressing 
CCK, somatostatin, calbindin, and neuropeptide Y.  Thus, future experiments in the lab 
will seek to colocalize one of these 4 interneuronal markers with Gαq, since that is the G 
protein known to increase L-type current.   One hypothesis is that increased intracellular 
calcium drives the maturation of one or more of these interneuronal types.  Although 
there are 16 different interneuron classes, it is likely that not all classes mature during 
development in the same way (Levitt et al., 2004).  One popular mechanism for 
maturation is activity-dependent regulation of gene expression.  Influx of calcium, 
particularly though N-methyl-ᴅ-aspartate (NMDA) or L-type calcium channels triggers a 
signaling cascade that is necessary for differentiation, growth, and/or formation of 
synaptic connections (West et al., 2002).  It has been shown that both neuronal calcium 
channel isoforms Cav 1.2 and Cav 1.3 colocalize with PV+ neurons.  Furthermore, 
although these interneurons express both isoforms, levels of Cav 1.3 are more widely 
expressed (Jiang and Swann, 2005).  This was a unique finding because it has been 
demonstrated previously that approximately 80% of total L-type channels are Cav 1.2 and 
only the remaining 20% are Cav 1.3 (Hell et al., 1993).  This study suggested that influx 
of calcium through Cav 1.3 regulated development of these PV+ interneurons via an 
unknown mechanism.  This is particularly interesting to our laboratory as we try to 
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identify the calcium channel isoform mediating current enhancement. The idea that a 
particular isoform of L-channels can regulate a particular class of interneurons is unique; 
it is also intriguing to consider whether L-type current enhancement is a requirement in 
neurons that depend on L-type current for maturation.   It is unlikely that the cells 
examined by Jiang and Swann (2005) may be those that show enhanced colocalization 
with Gαq and undergo current enhancement, because GABAB receptors do not colocalize 
with PV+ interneurons. 
 
L-type current controls gene expression 
The timing of L-type current enhancement is of particular interest given that this 
type of current is known to regulate gene expression (Figure 6.3).  The best-described 
mechanism for this regulation is through activation of transcription factors.  For example, 
local entry of L-type current is known to activate calcineurin (Norris et al., 2002), a 
protein phosphatase that dephosphorylates the transcription factor NFATc within the 
cytoplasm.  This dephosphorylation serves as a nuclear translocation signal, whereby 
NFATc will enter the nucleus and activate gene expression (Chung and Jan 2006).   Other 
intermediaries, such as CaMK IV or Ras/mitogen-activated protein kinase (MAPK) 
pathways also serve to transmit local rises in L-type current to global changes in gene 
expression (Dolmetsch et al., 2001).  Interestingly, these pathways involve the 
phosphorylation of transcription factor calcium/cAMP responsive element binding 
protein (CREB); activation of GABAB receptors has been shown to induce increases in  
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the ratio of phosphorylated CREB to nonphosphorylated CREB, and this increase can be 
blocked by treatment with L-type calcium channel antagonist nifedipine (Kuczewski et 
al., 2011).   
More recently, a fragment of Cav 1.2 (termed calcium channel associated 
transcription factor, or CCAT) has been shown to be cleaved from the full-length protein 
and act as a transcription factor (Gomez-Ospina et al., 2006).  While the mechanism of 
cleavage remains unclear, increasing L-type calcium current reduces the amount of  
CCAT-mediated transcription that occurs.  Furthermore, based on microarray data, 
expression of a host of genes was shown to be both upregulated and downregulated based  
on CCAT activity.  One of the genes that showed the greatest increases in expression 
upon CCAT recruitment to its promoter was connexin 31.1 (Cx31.1).  Connexins are 
proteins critical for the formation of direct electrical connections via gap junctions.  The 
synchronous firing pattern of interneurons is often dependent on gap junctions made up  
of this connexin, and CCAT has been demonstrated to be prominently expressed in these  
 
cells (Connors and Long 
2004).  It is tempting to 
speculate that 
enhancement of L-type 
current may specifically 
play a role in formation of 
CCAT-mediated 
expression of Cx31.1.  
Figure 6.3: Regulati n of 
gene expression by L-type 
channels.  When L-type 
channels are open, local 
calcium signals are 
transduced by second 
messengers, activating gene 
expression.  When calcium 
is low in the cell, the C-
terminal of the L-type 
channel is cleaved, and 
tr nslocat s to the nucleus 
to act as a transcription 
factor Reprinted from 
Nueron, 52(6). Chung H.J 
and Jan L.Y., Channeling to 
the nucleus, pp 937-940, 
Copyright (2006), with 
permission from Elsevier.  
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cells (Connors and Long 2004).  It is tempting to speculate that enhancement of L-type 
current may specifically play a role in CCAT-mediated expression of Cx31.1.  One 
hypothesis is that as the inhibitory circuitry matures and direct electrical connections are 
made, the level of Cx31.1 needs to be downregulated.  By P7, when enhancement of L-
type current is greatest (Bray and Mynlieff 2011), Cx31.1 expression is inhibited, such 
that exact electrical coupling between classes of interneurons is precisely controlled.  
Would eliminating L-type current enhancement lead to aberrant electrical connections? 
Future experiments could be designed to look at CCAT levels or Cx31.1 expression in 
neurons that demonstrate L-type enhancement.  If so, this would be evidence for the 
specific function of Cav isoform 1.2, as neither the Cav 1.3 isoform nor the N-type 
channel (Cav 2.1) C termini demonstrated any effect on transcription (Gomez-Ospina et 
al., 2006).   
 
Isozyme-specific function of PKCα in L-type current enhancement 
The regulation of calcium channels by PKC has been a matter of some 
controversy. The nonselective PKC activator PMA has been shown to enhance calcium 
current in Aplysia bag neurons (DeRiemer et al., 1985), neuroblastomas (Osugi et al., 
1986), and frog sympathetic neurons (Yang and Tsien 1993).  Paradoxically, inhibition of 
calcium current has been reported in chick dorsal root ganglion cells (Rane and Dunlap 
1986) and PC-12 cells (a neuroendocrine tumor cell line, Di Virgilio et al., 1986).  Even 
in the same cells, the effect of PKC stimulation can lead to opposite effects on calcium 
current (Tseng and Boyden 1991).  Thus, to define the actions of PKC requires the 
identification of the isozyme of PKC that is active in a particular pathway.  In cardiac Cav 
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1.2 channels, phosphorylation by PKCε on the N terminus is responsible for inhibition of 
L-type current (Yue et al., 2004).  However, the serine at position 1928 on the Cav 1.2 C 
terminus has been demonstrated to be phosphorylated by multiple PKC isoforms in 
HEK293 cells, including PKCα (Yang et al., 2005). This phosphorylation led to an 
increase in L-type channel activity.  Conversely, stimulation with PMA decreases the 
activity of Cav 1.3, mediated by PKCβII and PKCε (Baroudi et al., 2006).  These results 
are not inconsistent with data presented here, since enhanced L-type current in cultured 
neurons is due to the actions of PKCα rather than PKCβ or PKCε.  These studies also 
support the hypothesis that PKC is interacting with the L-type channel directly, rather 
than working through an intermediary.  Furthermore, PKC is thought to associate with 
the plasma membrane via binding a receptor for activated C kinase (RACK) protein, 
which is generally in proximity to the target substrate (Kamp and Hell 2000).  Studies 
designed to examine whether L-type channels colocalize or form complexes with RACKs 
would provide compelling evidence that PKCα does indeed directly phosphorylate L-
channels.  This isozyme-specific regulation is also suggestive that enhancement is 
occurring through Cav 1.2, and that inhibitory effects may reflect phosphorylation of Cav 
1.3.  It will be interesting to examine whether selective knockdown of Cav 1.3 leads to a 
greater proportion of neurons demonstrating current enhancement.  It is possible that the 
temporal expression of Cav 1.2 and 1.3 plays a key role in governing PKC-dependent 
enhancement of L-type current.    
Data presented here describe a signal transduction pathway initiated by GABAB 
receptor activation, resulting in enhanced L-type current in the developing mammalian 
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nervous system.  Proposed experiments will help decipher what the physiological 
relevance of this enhancement may be.   
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APPENDIX I 
The expression of interneuronal marker GAD6 in cultured hippocampal neurons 
In order to examine the effects of GABAergic stimulation on calcium currents, 
my studies have relied heavily on the use of P6-8 rat pups.  Hippocampal cultures from 
these pups have demonstrated the greatest number of neurons that demonstrate L-type 
current enhancement, as opposed to either older or younger pups.  Cells grown in culture 
are derived specifically from the superior region of the hippocampus, primarily CA1.  
Within this region, there are both inhibitory interneurons and excitatory pyramidal cells.  
Inhibitory interneurons, found primarily in the stratum oriens and stratum radiatium of 
the CA1 region, are more sparsely distributed relative to the excitatory neurons in the 
pyramidal layer. Because tissue from the superior region of the hippocampus was known 
to contain both excitatory and inhibitory neurons, a common question centers on the 
makeup of these neurons in culture.  This question is particularly important to work 
presented here, because the GABAB mediated enhancement of L-type current is only 
observed in a minority of neurons.  Since excitatory pyramidal cells compose a large 
percentage of total neurons in the hippocampus, it is not likely these are the neurons that 
demonstrate this effect.  Instead, my work has focused on GABAergic interneurons that 
provide inhibitory input to the pyramidal cells.  It follows that cell cultures which contain 
a relatively high population of interneurons would be best to study, because more cells 
would demonstrate the enhancement in which I am interested.  However, in embryonic 
cultures from rats aged E17-20, there are reports of cultures enriched in pyramidal 
neurons (Banker and Cowan 1977).  This is in contrast to reports that suggest significant 
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numbers of inhibitory neurons in embryonic cultures using anti-GABA antibodies 
(Mattson and Kater 1989).  Understanding the makeup of the cells in culture may offer 
explanations as to why only a certain subset of neurons demonstrates GABAB receptor-
mediated enhancement of L-type current. 
 Studies performed in the laboratory have examined the percentage of cells in 
culture that are immunoreactive for the GABA antibody, and thus assumed to be 
GABAergic inhibitory interneurons (Figure A1.1).  37.5 ± 2.3% of neurons showed 
GABA labeling after 24 hours in culture (Mynlieff 1997).  This labeling was independent 
of age; there was no significant difference in GABA labeling in neurons cultured from a 
P7, P14, or P21 animal.  When left in culture for longer periods, GABA labeling was 
seen in more cells.  Neurons cultured from a P21 animal and grown in vitro for 21 days 
demonstrated that 74.2 ± 2.7% of cells were labeled with anti-GABA antibodies 
(Mynlieff 1997).  Furthermore, this report only gives the number of cultures examined 
and not the total number of neurons labeled, so it is difficult to know how many cells 
were examined.   
 
 
 
 
 
 
 
 
Figure A1.1: Examples of GABA immunoreactive neurons in culture.  A: Neurons from a P11 
rat pup were dissociated and allowed to remain in culture 40 hours before fixation.  Neurons 
were labeled with mouse anti-GABA primary antibodies, and biotinylated anti-mouse IgG were 
used as the secondary antibodies.  Binding was visualized using a Vectastain Elite ABC Kit with 
a DIC microscope outfitted with Hoffman modulation optics.  B: Cultured cell control with tissue 
taken from the same pup as in A. (From Mynlieff 1997) 
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 I sought to verify these results using antibodies against glutamic acid 
decarboxylase (GAD).  GAD catalyzes the conversion of glutamate to GABA and carbon 
dioxide. Thus, GAD is universally expressed in GABAergic cells.  Neurons that express 
GABA must also express this enzyme.  There are two genes which encode two isoforms 
of GAD, GAD 65 and GAD 67, respectively.  The antibody against GAD that was used 
(GAD6) recognizes both isoforms.  Using confocal microscopy, a total of 43 of 287 
(14.98%) cells, isolated from 4 different animals, labeled for GAD.  The total number of 
cells is a sum taken from 11 different images.  As expected, labeling is largely absent in 
the nucleus.  Furthermore, there are no gradations in labeling.  It is clear which neurons 
express GAD (Figure A1.2), and are therefore assumed to be GABAergic interneurons.  
Notably, all neurons were isolated from P7 rat pups and kept in culture for 24 hours.  The 
effect of age or time in culture was not examined. 
 
  
 
 
 
 
 
 
 
 
Figure A1.2: Examples of GAD6 immunoreactive neurons in culture.  Neurons from a P7 rat pup 
were dissociated and allowed to remain in culture overnight before fixation.  Cells were decorated 
with anti-GAD6 primary antibodies and DyLight 550® secondary antibodies.  A: DAPI was 
applied to visualize nuclei.  B: GAD6 immunolabeling was not seen in the nuclei, but was around 
the periphery, often with a spot of particularly heavy labeling.  GAD6 was also seen in the 
processes of several neurons. C: Overlay of panels A and B. 
 
A. B. C. 
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The immunohistochemistry performed here shows dramatically fewer neurons 
than data from (Mynlieff 1997).  One possibility is that the antibody used by Mynlieff 
was not as specific as the GAD antibody.  There are inherent difficulties in producing 
antibodies to GABA.  Production of an antibody to a small molecule such as GABA 
requires it to be conjugated to a larger molecule; furthermore, the synthesis of GABA 
from glutamic acid involves removal of a carboxyl sidegroup.  These problems could lead 
to production of an antibody that may recognize more than its desired target.  Another 
possibility is that the resolution using confocal microscopy was better suited to discern 
which neurons were GABAergic.  Interpreting the images seen with biotinylation, 
visualized under differential interference contract (DIC) microscopy may be unclear such 
that shadows or cells with a generally darker appearance may be considered positive.  
Confocal imaging with GAD6 antibodies provided clear images that were easily 
quantified.   
 Hippocampal cultures containing less than 15% inhibitory interneurons has 
important implications for how data are interpreted.  The current hypothesis is that since 
not all neurons show GABAB receptor-mediated calcium current enhancement, there 
must be a subset of inhibitory interneurons that function differentially to account for this 
phenomenon.  However, one possibility is that the calcium current enhancement is a 
much more generalized effect.  Based on the percentage of neurons that demonstrate 
enhanced calcium entry when ratiometric calcium imaging is used, perhaps nearly all 
inhibitory interneurons exhibit this effect.  Indeed, while work in the Mynlieff laboratory 
has shown calcium current enhancement to occur in only a subset of cells, other reports 
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do not observe the same effect.  Thus, it is possible that current enhancement is always 
observed when inhibitory interneurons are selected.   
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APPENDIX II 
Inhibition of calcium channels by dihydropyridines as measured with ratiometric 
calcium imaging 
 The focus of my work has been to understand the G protein coupled pathway 
through which L-type calcium current is enhanced.  This current enhancement was shown 
to occur through L-type channels, because when L-channels were blocked with 
nimodipine, enhancement was eliminated.  However, the currents recorded either with 
electrophysiology or the calcium entry recorded with calcium imaging, likely effects 
opening of all types (L-, N-, P/Q-, R-, and T) of calcium channels.  Depending on the 
expression of each of these channels, whole cell calcium current may look very different 
from cell to cell.  Furthermore, cultured cells from CA1 are not heterogeneous, so it is 
likely that there are many different cell types, and even within cell types, calcium current 
profiles will vary.  It is important to this work to understand the relative contribution of 
L-type channels to whole cell calcium currents.   
Particularly in calcium imaging, separation of current types with toxins is cost 
prohibitive because there is constant perfusion occurring.  Instead through a combination 
of pharmacological methods and reliance on known channel kinetics, statements can be 
made about the type of channel through which calcium enters.  For example, 
dihydopyridines nimodipine and nifedipine are selective blockers of L-type calcium 
channels.  L-type current derives its name because it shows little voltage dependent 
inactivation (and thus is considered Long-lasting).   Understanding the total makeup and 
contribution of channels becomes important when trying to uncover roles for that 
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particular channel.  Electrophysiological recordings done in the Mynlieff laboratory by a 
previous graduate student demonstrated that L-type calcium current made up less than 
10% of total calcium current and was even lower in certain interneuronal classes (Figure 
A2.1).  For example, only about 5% of total calcium current was inhibited by L-type 
channel antagonist nimodipine when applied to basket cells.  However, this may be an 
underestimate, since in all cases except that of vertical cells, more than 50% of current is 
not blocked by N-, P/Q-, and L-channel antagonists.  Initial studies measuring the 
contribution to L-type current using ratiometric calcium imaging suggested entry through 
L-channels was greater than that shown using electrophysiology; therefore I sought to 
clarify the percentage of calcium entry flowing through L-channels using calcium 
imaging and two different dihydropyridine inhibitors.    
 
 
 
 
 
 
 
 
 
 
Several reports in the literature have attempted to describe the contribution of each type 
of calcium channel to total calcium current, and each has slightly different conditions.  
Figure A2.1: Components of whole-cell 
barium current in interneurons as measured by 
whole-cell patch clamp electrophysiology.  
Current-clamp measurements of action 
potentials were elicited by injecting a 0.1 – 0.2 
ms depolarizing current of 2 – 4 nA, followed 
by a switch to voltage clamp mode for 
measurements of calcium currents.   Barium 
currents were elicited from a holding potential 
of -80 mV by a 300 ms long depolarizing pulse 
to +10 mV.  Action potential kinetics allowed 
interneurons to be categorized into classes.  
Calcium channel inhibitors were used to 
separate components of whole cell current.  
Nimodipine was applied at 5 μM, GVIA was 
applied at 3 μM.  From (Carter 2002).   
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For example, hippocampal cultures performed on newborn rats were grown in culture for 
10-12 days.  L-type current was found to be 22.7 ± 5.2% of total current (Isaeva et al., 
1998).  Another study used neurons derived from E18 hippocampi.  This report described 
an age-dependent increase in L-type current, with the late component rising twofold from 
P7 to P21 (Blalock et al., 1999).  This study achieved a 40% block with nimodipine when 
cells were kept in culture 21 days. A third study noted the difference in the component of 
L-type current based on how long cells are kept in culture (Chameau et al., 1999). E16-18 
pups were grown in culture for 4 days.  When treated with nifedipine, 40% of total 
current was blocked.  This is in contrast to cells grown in culture for 16 days.  In these 
neurons, only 7% of calcium was blocked with the dihydropyridine antagonist.  In 
hippocampal slices of P15 – P29 rats, neurons of the entorhinal cortex showed the 
greatest sensitivity to dihydropyridines, where 52-55% of current was blocked when 
nifedipine was applied.  Thus, it appears L-type as a proportion of total current is highly 
variable depending on recording and culturing conditions.   
Thus, I sought to repeat these studies and examine levels of L-channel activity 
demonstrated in ratiometric calcium imaging, where the stimulation period is 3 orders of 
magnitude longer (300 ms stimulation for electrophysiological recordings compared to 30 
s in calcium imaging).  Two structurally similar dihydropyridines, nimodipine and 
nifedipine, were used to inhibit L-type channels.  Neurons were first depolarized with a 
high KCl solution to obtain a control value.  Once it was washed away and cells returned 
to baseline, the dihydopyridine was added for 15 seconds; KCl and the drug were 
coapplied for 30 seconds.  The response with the drug and high KCl (treatment) was 
compared to the response with high KCl alone (control).   
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When nifedipine (20 μM) was applied, 33.91 ± 1.50% of the high KCl-induced 
response was blocked, suggesting this was the component of total calcium entry that 
entered via L-type channels (N = 278); when nimodipine (20 μM) was applied, 37.73 ± 
1.39% of the response was blocked, (N = 381).  These data are summarized in figure 
A2.2.  Furthermore, of the 659 total cells tested, only 4 showed a blockage of greater than 
90%.  These data suggest that when measured via ratiometric calcium imaging, L-type 
current makes up a larger percentage of total calcium entry than what is observed with 
electrophysiology.  This percentage falls within the reported values for the contribution 
of L-current in other systems.   
 
 
 
 
 
 
 
 
 
 
Figure A2.2: Dihydropyridine sensitivity of cultured hippocampal neurons as measured with 
ratiometric calcium imaging.  High KCl was used to depolarize P7 cultured cells for 30 seconds.  
KCl was perfused off, and calcium levels returned to baseline before pretreatment with either 
nifedipine or nimodipine for 15 seconds.  Either nimodipine or nifedipine (20 μM) plus high 
KCl were coapplied for 30 s.  Each bar represents the percentage of L-type current blocked 
when compared with the normalized high KCl-alone response.   Error bars represent SEM.  
 
121 
 
Understanding the relative contribution of L-type entry to total entry has 
important implications.  Given the inherent variability of the system, questions may arise 
as to whether resolving small magnitude changes are accurate.  For example, if one is 
measuring the ratio of calcium entry and records a baseline value of 0.30 and a peak 
value of 0.90, the influx through voltage-gated channels would be 0.6.  Contribution of L-
type channels would only account for approximately 30% of this change, or 0.18.  
Therefore, it is possible that only cells which respond more robustly to high KCl 
stimulation should be considered for analysis.  This would be particularly true in studies 
measuring enhancement where knockdown of either neuronal Cav 1.X isoform is 
performed, and the contribution of only a single isoform is measured. 
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